<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006239.pub2" GROUP_ID="DEPRESSN" ID="110705040710262970" MERGED_FROM="" MODIFIED="2014-07-07 15:41:21 +0100" MODIFIED_BY="Jessica Sharp" REVIEW_NO="K07" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2014-07-07 15:41:21 +0100" MODIFIED_BY="Jessica Sharp">
<TITLE MODIFIED="2012-12-11 09:27:45 +0000" MODIFIED_BY="Chris Champion">Pharmacological interventions for preventing post-traumatic stress disorder (PTSD)</TITLE>
<CONTACT MODIFIED="2014-07-07 15:41:21 +0100" MODIFIED_BY="Jessica Sharp"><PERSON ID="14177418716966590049110526110219" ROLE="AUTHOR"><FIRST_NAME>Taryn</FIRST_NAME><LAST_NAME>Amos</LAST_NAME><EMAIL_1>tarynamos@gmail.com</EMAIL_1><MOBILE_PHONE>0833200071</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Education Centre, Valkenberg Hospital</ADDRESS_1><ADDRESS_2>Private Bage X1, Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 404 5483</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-07-07 15:41:21 +0100" MODIFIED_BY="Jessica Sharp"><PERSON ID="14177418716966590049110526110219" ROLE="AUTHOR"><FIRST_NAME>Taryn</FIRST_NAME><LAST_NAME>Amos</LAST_NAME><EMAIL_1>tarynamos@gmail.com</EMAIL_1><MOBILE_PHONE>0833200071</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Education Centre, Valkenberg Hospital</ADDRESS_1><ADDRESS_2>Private Bage X1, Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 404 5483</PHONE_1></ADDRESS></PERSON><PERSON ID="6972" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dan</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Stein</LAST_NAME><POSITION>Professor &amp; Chair</POSITION><EMAIL_1>dan.stein@uct.ac.za</EMAIL_1><URL>http://uct.academia.edu/DanStein</URL><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Education Centre, Valkenberg Hospital</ADDRESS_1><ADDRESS_2>Private Bage X1, Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389161</PHONE_1><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON><PERSON ID="18674" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Ipser</LAST_NAME><EMAIL_1>jonathanipser@gmail.com</EMAIL_1><EMAIL_2>jonathanipser@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>J-Block, Groote Schuur Hospital</ADDRESS_1><ADDRESS_2>Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-03-12 13:20:32 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="14" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="2" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="6" MONTH="9" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="7" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-02 08:56:24 +0100" MODIFIED_BY="Chris Champion"/>
<HISTORY MODIFIED="2014-06-29 09:06:23 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-29 09:06:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Cape Town, Cape Town</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>MRC Research Unit on Anxiety and Stress Disorders, Cape Town</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>MRC Research Unit on Anxiety and Stress Disorders, Cape Town</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-07-01 14:10:49 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-07-01 14:09:28 +0100" MODIFIED_BY="[Empty name]">Medications to prevent post-traumatic stress disorder (PTSD): a review of the evidence</TITLE>
<SUMMARY_BODY MODIFIED="2014-07-01 14:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Who may be interested in this review?</B>
</P>
<P>- People affected by PTSD and their families.<BR/>- Professionals working in adult mental health services.<BR/>- General practitioners.<BR/>- Charities that support victims of trauma or members of the armed forces.</P>
<P>
<B>Why is this review important?</B>
</P>
<P>PTSD is a condition experienced by some people after traumatic experiences such as warfare or domestic violence. People with PTSD experience symptoms of intense fear, helplessness and horror. Research suggests that changes in stress hormones in the brain may contribute to PTSD. Giving people medications which work in the brain soon after traumatic events may be able to prevent PTSD from developing.</P>
<P>Previous reviews have shown that talking therapy (cognitive behavioural therapy - CBT) is effective in preventing PTSD. This is the first review of medication as a preventative treatment for PTSD.</P>
<P>
<B>What questions does this review aim to answer?</B>
</P>
<P>- Is medication an effective preventative treatment for PTSD compared to placebo (dummy pills)?<BR/>- Is medication an acceptable treatment (do people stop medication due to side effects)?</P>
<P>
<B>Which studies were included in the review?</B>
</P>
<P>We searched databases to find all studies comparing medication with placebo for the prevention of PTSD, published up until February 2014. To be included in the review, studies had to be randomised controlled trials. Studies were included if they had adult participants aged over 18 who had experienced traumatic events but did not have a diagnosis of PTSD at the time of starting medication.</P>
<P>We included nine studies with a total of 345 participants in the review. Seven out of the nine studies had a high risk of bias due to problems with the research design.</P>
<P>
<B>What does the evidence from the review tell us?</B>
</P>
<P>There was moderate quality evidence that hydrocortisone (a steroid medication) prevented PTSD.</P>
<P>There was moderate quality evidence that hydrocortisone reduced the severity of PTSD symptoms.</P>
<P>There was no evidence that propranolol (a beta-blocker), escitalopram (a type of antidepressant), temazepam (a tranquillizer) or gabapentin (an anticonvulsant) prevented PTSD.</P>
<P>All medications were acceptable, with low numbers of people dropping out due to side effects; however not all studies provided information on this.</P>
<P>
<B>What should happen next?</B>
</P>
<P>The review authors do not feel there is sufficient evidence yet to recommend any medication as a preventative treatment for PTSD. The review authors recommend that future high quality research is needed to provide stronger evidence for the effectiveness of medications in preventing PTSD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-03 13:01:00 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-07-01 16:19:09 +0100" MODIFIED_BY="[Empty name]">
<P>Post-traumatic stress disorder (PTSD) is a debilitating disorder which, after a sufficient delay, may be diagnosed amongst individuals who respond with intense fear, helplessness or horror to traumatic events. There is some evidence that the use of pharmacological interventions immediately after exposure to trauma may reduce the risk of developing of PTSD.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-05-09 09:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of pharmacological interventions for the prevention of PTSD in adults following exposure to a traumatic event.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-07-02 08:58:11 +0100" MODIFIED_BY="Chris Champion">
<P>We searched the Cochrane Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies and CCDANCTR-References) (to 14 February 2014). This register contains relevant reports of randomised controlled trials from the following bibliographic databases: CENTRAL (all years); EMBASE (1974 to date); MEDLINE (1950 to date) and PsycINFO (1967 to date). We identified unpublished trials by searching the National Institute of Health (NIH) Reporter, the metaRegister of Controlled Trials database (mRCT) and the WHO International Clinical Trials Registry Platform (to December 2013). We scanned the reference lists of articles for additional studies. We placed no constraints on language and setting.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-07-01 14:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>We restricted studies to randomised controlled trials (RCTs) of pharmacological interventions compared with placebo for the prevention of PTSD in adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (TA and JI) independently assessed trials for eligibility and inclusion based on the review selection criteria. We independently extracted sample, methodological, outcome and 'Risk of bias' data, as well as the number of side effects, from each trial and entered these into a customised data extraction form. We contacted investigators for missing information. We calculated summary statistics for continuous and dichotomous variables (if provided). We did not undertake subgroup analyses due to the small number of included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-03 13:01:00 +0100" MODIFIED_BY="[Empty name]">
<P>We included nine short-term RCTs (duration 12 weeks or less) in the analysis (345 participants; age range 18 to 76 years). Participants were exposed to a variety of traumas, ranging from assault, traffic accidents and work accidents to cardiac surgery and septic shock. Seven studies were conducted at single centres.<B> </B>The seven RCTs included four hydrocortisone studies, three propranolol studies (of which one study had a third arm investigating gabapentin), and single trials of escitalopram and temazepam. Outcome assessment measures included the Clinician-Administered PTSD Scale (CAPS), the 36-Item Short-Form Health Survey (SF-36) and the Center for Epidemiological Studies &#8211; Depression Scale (CES-D).</P>
<P>In four trials with 165 participants there was moderate quality evidence for the efficacy of hydrocortisone in preventing the onset of PTSD (risk ratio (RR) 0.17; 95% confidence interval (CI) 0.05 to 0.56; P value = 0.004), indicating that between seven and 13 patients would need to be treated with this agent in order to prevent the onset of PTSD in one patient. There was low quality evidence for preventing the onset of PTSD in three trials with 118 participants treated with propranolol (RR 0.62; 95% CI 0.24 to 1.59; P value = 0.32). Drop-outs due to treatment-emergent side effects, where reported, were low for all of the agents tested. Three of the four RCTs of hydrocortisone reported that medication was more effective than placebo in reducing PTSD symptoms after a median of 4.5 months after the event. None of the single trials of escitalopram, temazepam and gabapentin demonstrated evidence that medication was superior to placebo in preventing the onset of PTSD.</P>
<P>Seven of the included RCTs were at a high risk of bias. Differential drop-outs between groups undermined the results of three studies, while one study failed to describe how the allocation of medication was concealed. Other forms of bias that might have influenced study results included possible confounding through group differences in concurrent medication and termination of the study based on treatment response.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>There is moderate quality evidence for the efficacy of hydrocortisone for the prevention of PTSD development in adults. We found no evidence to support the efficacy of propranolol, escitalopram, temazepam and gabapentin in preventing PTSD onset. The findings, however, are based on a few small studies with multiple limitations. Further research is necessary in order to determine the efficacy of pharmacotherapy in preventing PTSD and to identify potential moderators of treatment effect.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-07-01 14:20:50 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-07-01 14:15:53 +0100" MODIFIED_BY="[Empty name]">
<P>Post-traumatic stress disorder (PTSD) is a widespread condition that has been recognised in the fourth edition of the Diagnostic and Statistical Manual (DSM-IV) as a pathological response to severe trauma (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). To fulfil the DSM-IV criteria for PTSD, an individual must have been exposed to a traumatic event; have at least one re-experiencing, three avoidance and two hyperarousal phenomena; and have had the symptoms for at least one month, with the symptoms causing clinically important distress or reduced day-to-day functioning. PTSD is labelled as acute for the first three months and chronic if it lasts beyond three months (<LINK REF="REF-Bisson-2010" TYPE="REFERENCE">Bisson 2010</LINK>).</P>
<P>There is evidence that PTSD is associated with substantial reductions in quality of life, a high co-morbidity of psychiatric and medical disorders, marked functional impairment and high economic costs (<LINK REF="REF-Erbes-2007" TYPE="REFERENCE">Erbes 2007</LINK>; <LINK REF="REF-Schnurr-2009" TYPE="REFERENCE">Schnurr 2009</LINK>; <LINK REF="REF-Solomon-1997" TYPE="REFERENCE">Solomon 1997</LINK>). A nationally representative mental health survey, the National Comorbidity Survey, discovered that between 50% and 60% of people in the United States are exposed to trauma during their lifetimes, with a lifetime incidence of PTSD of 10.4% for women and 5% for men (<LINK REF="REF-Kessler-1995" TYPE="REFERENCE">Kessler 1995</LINK>). A more recent replication of this survey discovered that as many as 3.5% of those interviewed had developed PTSD within the previous 12 months (<LINK REF="REF-Kessler-2005" TYPE="REFERENCE">Kessler 2005</LINK>). Higher prevalence rates have been found in African countries, with a reported PTSD lifetime prevalence in four post-conflict settings of 37.4% in Algeria, 28.4% in Cambodia, 15.8% in Ethiopia and 17.8% in Gaza (<LINK REF="REF-de-Jong-2001" TYPE="REFERENCE">de Jong 2001</LINK>).</P>
<P>Reviews of retrospective and prospective studies have been conducted to identify predictive factors distinguishing between people who subsequently develop PTSD and those who do not (<LINK REF="REF-Brewin-2000" TYPE="REFERENCE">Brewin 2000</LINK>; <LINK REF="REF-Ozer-2003" TYPE="REFERENCE">Ozer 2003</LINK>). The general finding is that proximal factors, such as social support and trauma intensity, are more strongly implicated in the subsequent development of PTSD than more distal factors (such as history of family psychopathology). While peri-traumatic stress dissociation may predict development of PTSD (<LINK REF="REF-Ozer-2003" TYPE="REFERENCE">Ozer 2003</LINK>), more than half of individuals who go on to develop PTSD are not diagnosed with acute stress disorder (ASD) (<LINK REF="REF-Bryant-2003" TYPE="REFERENCE">Bryant 2003</LINK>).</P>
<P>A range of<B> </B>mechanisms have been proposed to account for the development of PTSD. These include hypotheses focusing on: cognitive attributions about the treatment event (<LINK REF="REF-Massad-2006" TYPE="REFERENCE">Massad 2006</LINK>; <LINK REF="REF-Nickerson-2013" TYPE="REFERENCE">Nickerson 2013</LINK>); re-consolidation of negative memories (<LINK REF="REF-Besnard-2012" TYPE="REFERENCE">Besnard 2012</LINK>; <LINK REF="REF-Pitman-1989" TYPE="REFERENCE">Pitman 1989</LINK>); abnormalities associated with exposure to trauma in neurotransmitter (<LINK REF="REF-Krystal-2009" TYPE="REFERENCE">Krystal 2009</LINK>); neuroendocrine (<LINK REF="REF-van-Zuiden-2013" TYPE="REFERENCE">van Zuiden 2013</LINK>; <LINK REF="REF-Yehuda-2006" TYPE="REFERENCE">Yehuda 2006</LINK>) and neurobiological factors (e.g. glucocorticoid-associated hippocampal atrophy systems (<LINK REF="REF-Bremner-2004" TYPE="REFERENCE">Bremner 2004</LINK>; <LINK REF="REF-Sapolsky-2000" TYPE="REFERENCE">Sapolsky 2000</LINK>), and epigenetic mechanisms in which gene-environment factors place certain individuals at greater risk of developing PTSD (<LINK REF="REF-Heinzelmann-2013" TYPE="REFERENCE">Heinzelmann 2013</LINK>). A number of sophisticated models have been developed in order to integrate cognitive-affective and neurobiological factors (<LINK REF="REF-Shalev-2006" TYPE="REFERENCE">Shalev 2006</LINK>), which may constitute a focus for prevention interventions or management of PTSD.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-07-01 14:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>There are many approaches to PTSD prevention, the most common of which is psychotherapy. Controlled clinical trials suggest that cognitive behavioural therapy (CBT) is likely to be beneficial for the prevention of PTSD development in adults and children (<LINK REF="REF-Bisson-2010" TYPE="REFERENCE">Bisson 2010</LINK>; <LINK REF="REF-Gillies-2012" TYPE="REFERENCE">Gillies 2012</LINK>; <LINK REF="REF-Mueser-2008" TYPE="REFERENCE">Mueser 2008</LINK>; <LINK REF="REF-Van-Emmerik-2008" TYPE="REFERENCE">Van Emmerik 2008</LINK>), with other psychological interventions being less well supported (<LINK REF="REF-Mayou-2000" TYPE="REFERENCE">Mayou 2000</LINK>; <LINK REF="REF-Rose-2002" TYPE="REFERENCE">Rose 2002</LINK>; <LINK REF="REF-Ruzek-2001" TYPE="REFERENCE">Ruzek 2001</LINK>; <LINK REF="REF-Turpin-2005" TYPE="REFERENCE">Turpin 2005</LINK>). The relatively large body of evidence for the short- and long-term efficacy of medication treatment for PTSD indicates that medication may be effective in preventing PTSD; the most evidence of efficacy currently existing for the selective serotonin reuptake inhibitors (SSRIs), with promising initial findings for the selective noradrenergic reuptake inhibitor venlafaxine and the atypical antipsychotic risperidone (<LINK REF="REF-Ipser-2011" TYPE="REFERENCE">Ipser 2011</LINK>). Nevertheless, a recent multi-arm randomised controlled trial (RCT) of the SSRI escitalopram failed to observe a reduction in the onset of PTSD relative to placebo at five or nine months post-trauma exposure (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>). A similar lack of evidence of efficacy was observed for the antidepressants imipramine and fluoxetine in reducing ASD symptoms in paediatric burn victims (<LINK REF="REF-Robert-2008" TYPE="REFERENCE">Robert 2008</LINK>), despite initial promising findings in this population in a RCT of imipramine (<LINK REF="REF-Robert-1999" TYPE="REFERENCE">Robert 1999</LINK>).</P>
<P>Several additional classes of medication may be useful in the prevention of PTSD. Findings from controlled trials of the beta-adrenergic antagonists, such as propranolol (<LINK REF="REF-Brunet-2008" TYPE="REFERENCE">Brunet 2008</LINK>), and glucocorticoids such as hydrocortisone (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>), are promising and support suggestions that cortisol administration after trauma may be a useful approach in preventing PTSD (<LINK REF="REF-Schelling-1999" TYPE="REFERENCE">Schelling 1999</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>). While benzodiazepines are widely used in acute trauma settings, the rationale for their use in treating trauma has been undermined by the negative findings of a non-randomised controlled trial of clonazepam or alprazolam (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>). Early administration of temazepam following life-threatening incidents actually resulted in a larger proportion of participants developing PTSD in a small randomised, placebo-controlled trial (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>). A randomised controlled trial of gabapentin did not provide evidence for the efficacy of anxiolytic anticonvulsants in preventing PTSD (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Abnormal cortical secretion resulting from disruptions in HPA axis functioning in PTSD has been widely documented (<LINK REF="REF-Meewisse-2007" TYPE="REFERENCE">Meewisse 2007</LINK>), with reports of lower urinary and plasma cortisol in PTSD suggesting that administering cortical steroids to individuals at risk of PTSD might prove beneficial in preventing the onset of the disorder (<LINK REF="REF-Yehuda-1990" TYPE="REFERENCE">Yehuda 1990</LINK>; <LINK REF="REF-Yehuda-2008" TYPE="REFERENCE">Yehuda 2008</LINK>). Although the precise mechanism through which glucocorticoids might prevent PTSD is not clear, animal and human studies have identified complex effects of cortisol administration on memory for emotionally arousing events (<LINK REF="REF-de-Quervain-2009" TYPE="REFERENCE">de Quervain 2009</LINK>). Specifically, high levels of glucocorticoids appear to improve the initial consolidation of memory for traumatic events, but have detrimental effects on the subsequent recall of these events. Additionally, a substantial body of evidence reviewed by <LINK REF="REF-de-Quervain-2009" TYPE="REFERENCE">de Quervain 2009</LINK> indicates that the effects of glucocorticoids on traumatic memory are modulated by noradrenergic release in response to stress (<LINK REF="REF-Nicholson-2013" TYPE="REFERENCE">Nicholson 2013</LINK>), particularly in the basolateral amygdala (BLA). The reduced incidence of PTSD in a case-control (<LINK REF="REF-Schelling-1999" TYPE="REFERENCE">Schelling 1999</LINK>) and a randomised controlled trial (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>) of hydrocortisone in patients being treated for septic shock has accordingly been explained in terms of the steroid redressing the low levels of cortisol in combination with elevated levels of noradrenaline typically found in this patient population.</P>
<P>According to Pitman's translational model of PTSD pathogenesis (<LINK REF="REF-Pitman-1989" TYPE="REFERENCE">Pitman 1989</LINK>; <LINK REF="REF-Pitman-2005" TYPE="REFERENCE">Pitman 2005</LINK>), agents that block the effect of stress hormones in the brain might be expected not only to reduce the emotional salience of aversive events, but also to disrupt the resulting over-consolidation of traumatic memories and reinforcement of those memory traces through rehearsal of the events. This is consistent with the finding in a controlled pilot study that administration of propranolol, an agent that acts to block post-synaptic beta-adrenergic receptors in the BLA, reduced psychophysiological reactivity to mental imagery (<LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>), as well as PTSD rate and symptom severity in a non-randomised trial in motor vehicle accident or assault victims (<LINK REF="STD-Vaiva-2003" TYPE="STUDY">Vaiva 2003</LINK>). Questions remain, however, regarding the relevance of the adrenalin consolidation hypothesis for indirect trauma (<LINK REF="REF-Ozer-2003" TYPE="REFERENCE">Ozer 2003</LINK>), as well as the possible harmful effects of beta-blockers such as propranolol in reducing the intensity of memory for traumatic events in the reconsolidation of traumatic memories (<LINK REF="REF-McCleery-2004" TYPE="REFERENCE">McCleery 2004</LINK>).</P>
<P>While the GABAergic system may also be involved in PTSD development, early work has not supported the use of benzodiazepines such as clonazepam, alprazolam and temazepam for PTSD prevention (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>). The anteretrograde amnesia induced by benzodiazepines and evidence from animal studies of their possible potentiation of the acquisition of fear responses (<LINK REF="REF-Hebert-1996" TYPE="REFERENCE">Hebert 1996</LINK>; <LINK REF="REF-Lumley-2000" TYPE="REFERENCE">Lumley 2000</LINK>) could explain the increased rates of PTSD observed following early use of benzodiazepines in controlled trials (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>). The risk of dependency associated with these medications might also make them a less suitable option.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-07-01 14:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the vast body of evidence on the treatment of PTSD, little is known about the use of pharmacological interventions for the prevention of PTSD. A number of Cochrane systematic reviews have been published in this area, but these have been restricted to psychological debriefing interventions (<LINK REF="REF-Rose-2002" TYPE="REFERENCE">Rose 2002</LINK>), multiple session early psychological interventions (<LINK REF="REF-Roberts-2010" TYPE="REFERENCE">Roberts 2010</LINK>), and psychosocial interventions (<LINK REF="REF-De-Silva-2009" TYPE="REFERENCE">De Silva 2009</LINK>; <LINK REF="REF-Pe_x00f1_alba-2009" TYPE="REFERENCE">Peñalba 2009</LINK>). A systematic review of randomised controlled clinical trials of medication for the prevention of PTSD would therefore help to characterise the extent to which pharmacotherapy can be considered as a viable alternative to psychotherapy as a secondary prevention strategy in the treatment of PTSD.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-05-14 07:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of pharmacological interventions for the prevention of PTSD in adults following exposure to a traumatic event.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-07-03 12:25:40 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>We considered all randomised controlled trials (RCTs) for inclusion irrespective of publication status or language.</P>
<P>We also included cluster-randomised control trials and studies with multiple treatment groups in the analysis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-07-01 14:21:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Participant characteristics</HEADING>
<P>We included in the review adult<B> </B>participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for post-traumatic stress disorder at study recruitment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Co-morbidities</HEADING>
<P>These individuals may or may not have been diagnosed with acute stress disorder, or with comorbid psychopathological disorders.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>We placed no restrictions on setting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subsets of participants</HEADING>
<P>We also included trials that included a subset of participants that met the review inclusion criteria in the analysis, provided data for this subset could be extracted from the study report.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-07-01 14:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>We considered any pharmacological interventions, administered with the express intent to prevent the onset of PTSD, compared with a placebo.</P>
<SUBSECTION>
<HEADING LEVEL="4">Experimental interventions</HEADING>
<P>We grouped specific pharmacological interventions according to medication class. These included the following:</P>
<UL>
<LI>Antipsychotics</LI>
<LI>Benzodiazepines</LI>
<LI>Beta-blockers</LI>
<LI>Selective serotonin reuptake inhibitors (SSRIs)</LI>
<LI>Serotonin and norepinephrine reuptake inhibitors (SNRIs)</LI>
<LI>Tricyclic antidepressants (TCAs)</LI>
<LI>Mono-amine oxidase inhibitors (MAOIs)</LI>
<LI>Other medications</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator interventions</HEADING>
<UL>
<LI>Placebo</LI>
</UL>
<P>We placed no restrictions on timing, dose, duration and co-interventions.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-07-03 12:25:40 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-07-01 14:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>1. Treatment efficacy: we determined treatment efficacy from the number of participants who developed PTSD after a minimum period of three months after the traumatic event (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). We determined diagnosis according to the relevant DSM-IV criteria (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>), as implemented in scales such as the Clinician-Administered PTSD Scale (CAPS) (<LINK REF="REF-Blake-1995" TYPE="REFERENCE">Blake 1995</LINK>), and the Comprehensive International Diagnostic Interview (CIDI) (<LINK REF="REF-WHO-1997" TYPE="REFERENCE">WHO 1997</LINK>). We also accepted outcomes from studies assigning a probable diagnosis of PTSD using the Posttraumatic Stress Symptom 10 Questionnaire Inventory (PTSS-10), given evidence that this measure has moderate to high (77%) sensitivity and excellent (97.5%) specificity in diagnosing clinically confirmed cases of PTSD (<LINK REF="REF-Weisaeth-1989" TYPE="REFERENCE">Weisaeth 1989</LINK>).</P>
<P>2. Treatment acceptability: we included the total proportion of participants who withdrew from the RCTs due to treatment-emergent side effects in the analysis as a surrogate measure of treatment acceptability, in the absence of other more direct indicators of acceptability.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-07-03 12:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>3. Reduction in PTSD symptoms: we assessed PTSD symptoms and, where available, symptom cluster response, using validated scales such as the CAPS (<LINK REF="REF-Blake-1995" TYPE="REFERENCE">Blake 1995</LINK>) and the PTSS-10.</P>
<P>4. Reduction in comorbid symptom responses measured by:<BR/>a. depression scales, such as the Hamilton Depression Scale (<LINK REF="REF-Hamilton-1959" TYPE="REFERENCE">Hamilton 1959</LINK>), and the Beck Depression Inventory (<LINK REF="REF-Beck-1961" TYPE="REFERENCE">Beck 1961</LINK>);<BR/>b. anxiety scales, such as the Hamilton Anxiety Scale (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>).</P>
<P>5. Quality of life measures, such as the MOS 36-Item Short-Form Health Survey (SF-36) (<LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>).</P>
<P>6. Measures of functional disability, such as the Sheehan Disability Scale (<LINK REF="REF-Sheehan-1996" TYPE="REFERENCE">Sheehan 1996</LINK>).</P>
<P>7. Side effects: we described the most common drug-related side effects for both the included and excluded studies (defined as those occurring in at least 20% of the participants given medication), as well as significant differences in the rate of occurrence of treatment-emergent side effects between medication and control groups, as part of the narrative review.</P>
<SUBSECTION>
<HEADING LEVEL="4">Main outcomes of 'Summary of findings' tables</HEADING>
<P>We compiled 'Summary of findings' tables to summarise the best evidence for all relevant outcomes (i.e. experimental versus comparator interventions), and these consisted of the following six elements using a fixed format (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>):</P>
<UL>
<LI>A list of all important outcomes, both desirable and undesirable.</LI>
<LI>A measure of the typical burden of these outcomes (e.g. illustrative risk, or illustrative mean, on control intervention).</LI>
<LI>Absolute and relative magnitude of effect (if both are appropriate).</LI>
<LI>Numbers of participants and studies addressing these outcomes.</LI>
<LI>A grade of the overall quality of the body of evidence for each outcome.</LI>
<LI>Space for comments.</LI>
</UL>
<P>Evidence for downgrading studies was based on five factors. If we found a reason for downgrading the evidence, we classified the evidence as 'serious' (downgrading the quality rating by one level) or 'very serious' (downgrading the quality grade by two levels):</P>
<UL>
<LI>Limitations in the design and implementation of the trial.</LI>
<LI>Indirectness of evidence.   </LI>
<LI>Unexplained heterogeneity or inconsistency of results.</LI>
<LI>Imprecision of results.</LI>
<LI>High probability of publication bias.</LI>
</UL>
<P>We classified the quality of evidence for each outcome according to the following categories:</P>
<UL>
<LI>High quality: further research is very unlikely to change our confidence in the estimate of effect.</LI>
<LI>Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</LI>
<LI>Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</LI>
<LI>Very low quality: we are very uncertain about the estimate.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Timing of outcome assessment</HEADING>
<P>We included data for outcomes from validated measures in the review. We determined treatment efficacy from the number of participants who developed PTSD after a minimum period of three months after the traumatic event (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). For studies that assessed outcomes at multiple time points (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), we synthesised data at the first time point that occurred at least three months after the index traumatic event, consistent with the DSM-IV criteria for chronic PTSD (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CCDAN's Specialised Register (CCDANCTR)</HEADING>
<P>The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) maintain two clinical trials registers at their editorial base in Bristol, UK, a references register and a studies-based register. The CCDANCTR-References Register contains over 35,000 reports of randomised controlled trials in depression, anxiety and neurosis. Approximately 60% of these references have been tagged to individual, coded trials. The coded trials are held in the CCDANCTR-Studies Register and records are linked between the two registers through the use of unique Study ID tags. Coding of trials is based on the EU-Psi coding manual. Reports of trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (January 1950 to date), EMBASE (January 1974 to date) and PsycINFO (January 1967 to date); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific searches of additional databases. Reports of trials are also sourced from international trials registers c/o the World Health Organization's trials portal (<A HREF="http://apps.who.int/trialsearch/">ICTRP</A>), drug companies and the handsearching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses. Details of <A HREF="http://ccdan.cochrane.org/search-strategies-identification-studies">CCDAN's generic search strategies</A> can be found on the Group's website.</P>
</SUBSECTION>
<ELECTRONIC_SEARCHES MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the CCDANCTR (Studies and References) (initially to April 2012) on condition alone (due to the ever-increasing list of pharmacological interventions used to prevent and treat PTSD).</P>
<P>Search terms used were: (PTSD or posttrauma* or post-trauma* or "post trauma*" or "combat disorder*" or "stress disorder*").</P>
<P>The Trials Search Co-ordinator (TSC) performed a final (more precise) update search on the CCDANCTR in February 2014, appending terms for prevention: ("early intervention" or prevent* or prophyla*).<BR/>All non-pharmacological (including omega-3) and/or paediatric studies were weeded out, together with those already identified by the author team.</P>
<P>Earlier searches were also conducted by CCDAN's TSC on MEDLINE (March 2011), using terms for PTSD in addition to a sensitive list of drug terms. These searches were instigated when the CCDANCTR was out of date, due to a change over of staff at the editorial base (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>The review authors additionally ran their own searches on PubMed, PsycINFO and EMBASE (March 2011) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We located ongoing or unpublished trials (December 2013) using the metaRegister of Controlled Trials database (mRCT) (<A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>), as well as the WHO clinical trials portal (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) and the National Institutes of Health (NIH) Reporter database (<A HREF="http://projectreporter.nih.gov/reporter.cfm">http://projectreporter.nih.gov/reporter.cfm</A>). We selected the NIH ClinicalTrials.gov register as one of the databases searched through the mRCT interface. We entered the search terms 'posttraumatic stress disorder' OR 'post traumatic stress disorder' OR 'PTSD' as search queries for these databases.</P>
<P>We conducted a systematic review search on OVID MEDLINE (April 2012) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>We scanned the bibliographies of all identified trials for additional studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Personal communication</HEADING>
<P>We also obtained published and unpublished trials from key researchers, as identified by the frequency with which they are cited in the bibliographies of RCTs and open-label studies.<BR/>
</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-07 15:08:09 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (TA and JI) independently assessed RCTs identified from the search for inclusion based on information included in the title and abstract. We subsequently scanned full-text articles agreed upon as potentially eligible. The authors independently collated the data listed under <LINK TAG="DATA_EXTRACTION" TYPE="SECTION">Data extraction and management</LINK> from RCTs which they both regarded as satisfying the inclusion criteria specified in the <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK> section. We listed studies for which additional information was required in order to determine their suitability for inclusion in the review in the <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> table, pending the availability of this information. We resolved any disagreements in the trial assessment and data collation procedures by discussion with a third review author (DS).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-07-01 14:31:19 +0100" MODIFIED_BY="[Empty name]">
<P>We designed spreadsheet forms for the purpose of recording descriptive information, summary statistics of the outcome measures and associated commentary. Two review authors (TA and JI) compiled these forms and independently extracted data. Once the data extraction process was complete, we rechecked both data sheets for any discrepancies. If these discrepancies could not be addressed by both review authors, we approached an additional review author (DS) for further clarification. Where information was missing, we contacted the investigators by email in an attempt to obtain this information.</P>
<P>We obtained the following information from each trial:</P>
<UL>
<LI>Description of the trials, including the primary researcher, the year of publication, source of funding, and the setting and/or location.</LI>
<LI>Characteristics of the interventions, including the dose of medication, the period over which it was administered and the name of the particular medication tested.</LI>
<LI>Characteristics of trial methodology, including the diagnostic (e.g. DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>)) and exclusionary criteria employed, the screening instrument used (e.g. the Structured Clinical Interview for DSM-IV (SCID) (<LINK REF="REF-Spitzer-1996" TYPE="REFERENCE">Spitzer 1996</LINK>)) for both the primary and comorbid diagnoses, the presence of comorbid major depressive disorder (MDD), the use of a placebo run-in, whether a minimal severity criterion was employed and the number of centres involved.</LI>
<LI>Characteristics of participants, including the number of participants randomised to the treatment and control groups, their age and gender distributions, whether they have been treated with the medication in the past (treatment naivety), whether they have a history of trauma, the number of participants in the sample with MDD, the type of trauma to which they were exposed, and the average time between trauma and treatment.</LI>
<LI>Outcome measures employed (primary and secondary), and summary continuous (means and standard deviations) and dichotomous (number of responders) data. We included additional information, such as the number of total drop-outs per group as well as the number that dropped out due to side effects. We kept records of whether the data reflected the intention-to-treat (ITT) with last observation carried forward (LOCF) or completer/observed cases (OC) sample, and the minimal period required for inclusion of participants in the LOCF analyses. We also recorded other methods of estimating the outcome for participants who dropped out of the study, such as the mixed-effects (ME) model.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Main comparisons</HEADING>
<P>We planned the following comparisons, based on the protocol for this review (with the post hoc addition of beta-blockers, see <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>):</P>
<UL>
<LI>Antipsychotics versus placebo</LI>
<LI>Benzodiazepines versus placebo</LI>
<LI>Beta-blockers versus placebo</LI>
<LI>Selective serotonin reuptake inhibitors (SSRIs) versus placebo</LI>
<LI>Serotonin and norepinephrine reuptake inhibitors (SNRIs) versus placebo</LI>
<LI>Tricyclic antidepressants (TCAs) versus placebo</LI>
<LI>Mono-amine oxidase inhibitors (MAOIs) versus placebo</LI>
<LI>Other medications versus placebo</LI>
</UL>
<P>Agents tested in the trials included in this review were the beta-blocker propranolol, the steroid hydrocortisone, the SSRI escitalopram, the anticonvulsant gabapentin and the benzodiazepine temazepam. Accordingly, we restricted comparisons for the treatment and control groups to the following:</P>
<UL>
<LI>Benzodiazepines versus placebo</LI>
<LI>Beta-blockers versus placebo</LI>
<LI>SSRIs versus placebo</LI>
<LI>Other medications (hydrocortisone, gabapentin) versus placebo</LI>
</UL>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-07-01 16:12:24 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of each included study using The Cochrane Collaboration 'Risk of bias' tool (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). We considered the following six domains:</P>
<OL>
<LI>Random sequence generation: referring to a random number table or using a computer random number generator?</LI>
<LI>Allocation concealment: was the medication sequentially numbered, sealed or placed in opaque envelopes?</LI>
<LI>Blinding of participants, personnel and outcome assessors for each main outcome or class of outcomes: was knowledge of the allocated treatment or assessment adequately prevented during the study?</LI>
<LI>Incomplete outcome data for each main outcome or class of outcomes: were missing or excluded outcome data adequately addressed?</LI>
<LI>Selective outcome reporting: were the reports of the study free of suggestion of selective outcome reporting?</LI>
<LI>Other sources of bias: was the study apparently free of other problems that could put it at a 'high' risk of bias.</LI>
</OL>
<P>We extracted relevant information from each study report, where provided. We made a judgement on the risk of bias for each domain within and across studies, based on the following three categories: 'low' risk of bias, 'unclear' risk of bias and 'high' risk of bias.</P>
<P>Two independent review authors (TA and JI) assessed the risk of bias in selected studies. We discussed any disagreements with a third review author (DJ). Where necessary, we contacted the authors of the studies for further information. All risk of bias data are presented graphically and described in the text.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-03 12:44:25 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Categorical data</HEADING>
<P>We calculated risk ratio of response to treatment and number needed to treat to benefit (NNTB) for the dichotomous outcomes of interest. We used risk ratio instead of odds ratio, as odd ratios are less easily interpreted. Odds ratios also tend to overestimate the size of the treatment effect relative to risk ratios, especially when the occurrence of the outcome of interest is common (as anticipated in this review, with an expected response greater than 20%) (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). The NNTB is based on the risk ratio and is computed with respect to an assumed incidence of PTSD following trauma exposure in the control group of 10% and 20% (<LINK REF="REF-Norris-2007" TYPE="REFERENCE">Norris 2007</LINK>). The NNTB provides a measure of the number of people who require treatment with medication, relative to a control, before a single additional person in the medication group responds to treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We calculated mean differences (MD) for continuous summary data derived from the same scale, such as the Clinician-Administered PTSD Scale (CAPS) for symptom severity. In cases in which a range of scales were employed for each outcome, such as in the assessment of comorbid depression on the Montgomery&#8211;Åsberg Depression Rating Scale (MADRS) and Hamilton Depression Scale (HAM-D), we determined the standardised mean difference (SMD). The SMD standardises the differences between the means of the treatment and control groups in terms of the variability observed in the trial.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-07-01 16:12:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>In cluster-randomised trials, groups of individuals rather than individuals are randomised to different interventions. Analysing treatment response in cluster-randomised trials without taking these groups into account is potentially problematic, as participants within any one cluster often tend to respond in a similar manner, and thus their data can no longer be assumed to be independent of one another. Cluster-randomised trials also face additional risk of bias issues including (a) recruitment bias, (b) baseline imbalance, (c) loss of clusters and (d) non-comparability with trials in which allocation of treatment is randomly assigned on the individual level (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). No cluster-randomised trials were eligible for inclusion in this review. To prevent unit of analysis errors in future updates of this review, we planned to divide the effective sample size of each comparison group in trials that did not adjust for clustering by the design effect metric (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), with the intraclass correlation coefficient (ICC) that is incorporated within the design effect set equivalent to the median ICC from published cluster-randomised pharmacotherapy RCTs for anxiety disorders.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>Studies with more than two intervention arms pose difficulties in the analysis of prevention data. We assessed such studies as follows:</P>
<SUBSECTION>
<HEADING LEVEL="5">Continuous data</HEADING>
<P>We pooled mean values, standard deviations and number of participants for each intervention group across treatment arms and compared them against the control group (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dichotomous data</HEADING>
<P>We combined experimental intervention groups into a single group for comparison against the control group, or divided out the shared intervention groups approximately evenly among the comparisons (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We only included cross-over trials in the calculation of summary statistics when it was (a) possible to extract medication and placebo/comparator data from the first treatment period, or (b) when the inclusion of these data from both treatment periods was justified through a wash-out period of sufficient duration as to minimise the risk of carry-over effects. We assessed the minimum wash-out period required on the basis of the plasma half-life of the particular agent, as determined by consulting the Lundbeck Psychotropics website (<LINK REF="REF-Lundbeck-2003" TYPE="REFERENCE">Lundbeck 2003</LINK>).</P>
<P>For cross-over trials in which the wash-out period was regarded as adequate, we only included data from both periods when it was possible to determine the standard error of the mean difference in response between groups (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). We obtained the summary statistics required to derive the standard error of interest from the trial report, or for trials for which this information was missing, we imputed them through averaging the relevant statistic from other included cross-over trials with comparable control conditions.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-07-01 14:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>All analyses of dichotomous data were intention-to-treat (ITT). We used the total number of participants randomised to the different comparison groups as the denominator in comparisons of treatment efficacy. We only included data from trials which provided information on the original group size (prior to drop-outs) in the analysis of treatment efficacy. In trial reports in which multiple forms of data imputation were conducted, we gave preference to the inclusion of summary statistics for continuous outcome measures derived from mixed-effects models (ME), followed by last observation carried forward (LOCF) and observed cases (OC) summary statistics (in that order). This is in line with evidence that ME methods are more robust to bias than LOCF analyses (<LINK REF="REF-Verbeke-2000" TYPE="REFERENCE">Verbeke 2000</LINK>). If data on studies, outcomes, summary data, participants or study-level characteristics were missing, we contacted the original investigators.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-07-03 12:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity by means of the Chi² test of heterogeneity to assess whether observed differences in results are compatible with chance alone. A low P value (or a large Chi² test relative to its degree of freedom) provides evidence of heterogeneity of intervention effects (variation in effect estimates beyond chance). We also assessed heterogeneity against a P value of 0.10. If the Chi² test had a P value of less than 0.10, we interpreted this as evidence of heterogeneity, given the low power of the Chi² test when the number of trials is small (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). In addition, we used the I² statistic, reported by RevMan, to quantify the inconsistency of the trial results within each analysis (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Thresholds for the interpretation of I² can be misleading, since the importance of inconsistency depends on several factors. A rough guide for interpretation was followed:</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity;</LI>
<LI>50% to 90%: may represent substantial heterogeneity;</LI>
<LI>75% to 100%: considerable heterogeneity.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to inspect funnels plots visually for evidence of reporting bias for the treatment efficacy and PTSD symptom reduction outcomes. Funnel plots provide a graphical illustration of the effect estimates of an intervention from individual studies against some measure of the precision of that estimate. However, we decided not to generate funnel plots as this would not have been informative, given the small number of studies included in the meta-analyses of these outcomes. For the same reason, we also decided to forgo additional planned Eggers' regression tests (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>), to confirm evidence of reporting bias from the funnel plots for the PTSD symptom reduction outcome. Future updates of the review will employ Egger's regression test if there are at least 10 studies providing data on this outcome (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-07-01 14:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>We obtained categorical and continuous treatment effects from a random-effects model. Random-effects analytic models include both within-study sampling error and between-study variation in determining the precision of the confidence interval around the overall effect size, whereas fixed-effect modelling approaches take only within-study variation into account. We expressed the outcomes in terms of an average effect size for each subgroup, as well as by means of 95% confidence intervals. We included a small sample bias corrected version of the Cohen's D effect size estimate, Hedges' g, as well as its 95% confidence intervals in the narrative review of study results that could not be synthesised (provided these data were normally distributed - see paragraph below), to aid in the interpretability of the magnitude of the medication effect. We calculated this statistic using the compute.es package within the R statistical computing language (<LINK REF="REF-Del-Re-2013" TYPE="REFERENCE">Del Re 2013</LINK>).</P>
<P>Evidence that data from individual studies were skewed was grounds for excluding the study from quantitative analysis. For the purposes of this review, the following constituted evidence of skewness: cases in which the difference between the observed mean and the lowest possible value or highest possible value on the scale is less than twice as large as the standard deviation (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>), or where data are reported as skewed by the authors. For future updates of this review we plan to obtain individual patient data (where possible) for the purpose of normalising the data by means of log transformation techniques.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>We planned subgroup analyses to assess the degree to which methodological differences between trials might have systematically influenced differences observed in the primary treatment outcomes (<LINK REF="REF-Thompson-1994" TYPE="REFERENCE">Thompson 1994</LINK>). Current guidelines recommend at least 10 studies per characteristic used for stratifying subgroups (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). Accordingly, we did not conduct subgroup analyses to determine the effect on the primary outcomes of whether trials were conducted at single or multiple treatment centres, were funded by pharmaceutical companies or included participants with major depression.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-07-07 15:08:09 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses are designed to test the robustness of review authors' conclusions to methodological assumptions made in conducting meta-analyses. We planned to assess whether treatment response varies as a function of the use of treatment response versus non-response as an outcome statistic. We regarded this comparison as necessary in light of evidence that treatment response may result in less consistent outcome statistics than non-response (<LINK REF="REF-Deeks-2002" TYPE="REFERENCE">Deeks 2002</LINK>), when the control group event rate is higher than 50%. No control group event rate was higher than 50% of the ITT sample for any of the studies included in this review, obviating the need for this analysis.</P>
<P>The dichotomous outcome of treatment response in this review is calculated as the proportion of participants diagnosed with PTSD at follow-up out of the total randomised sample. This effectively counts drop-outs in the comparison groups as responders to medication or placebo. We assessed the effect of the decision to use the randomised sample instead of the more commonly reported completer sample in a post hoc sensitivity analysis (e.g. <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> and <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We presented the main findings of the review, for the primary outcome of treatment efficacy, in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> using GRADEpro 3.6 software (<A HREF="http://ims.cochrane.org/gradepro">http://ims.cochrane.org/gradepro</A>). 'Summary of findings' tables present the main findings of a review in a transparent and simple tabular format. In particular, they provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on the main outcomes (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<P>We assessed five factors that decrease the quality level of a body of evidence:</P>
<UL>
<LI>Limitations in the design and implementation.</LI>
<LI>Indirectness of evidence.</LI>
<LI>Unexplained heterogeneity or inconsistency of results.</LI>
<LI>Imprecision of results.</LI>
<LI>High probability of publication bias.</LI>
</UL>
<P>We classified the quality of evidence for each outcome according to the following categories:</P>
<UL>
<LI>High quality: further research is very unlikely to change our confidence in the estimate of effect.</LI>
<LI>Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</LI>
<LI>Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</LI>
<LI>Very low quality: we are very uncertain about the estimate.</LI>
</UL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-07 15:09:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-07-02 09:08:01 +0100" MODIFIED_BY="Chris Champion">
<SEARCH_RESULTS MODIFIED="2014-07-01 15:36:24 +0100" MODIFIED_BY="[Empty name]">
<P>We found a total of 3992 study reports through the search process (CCDANCTR 2012, OVID MEDLINE 87, mRCT 285, NIH Reporter 941, WHO Trials 667). We scanned each title and abstract (if provided) for eligibility. Seventy-one studies initially seemed relevant, but further inspection excluded 50 of these, leaving 21 studies that potentially met the inclusion criteria. After independent reviewing of the full text for these studies, 12 failed to meet inclusion criteria, leaving nine RCTS eligible for inclusion in the review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Two of the nine eligible studies were identified (prior to the final updated search of the CCDANCTR) through searching reference lists (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>), and from editorial feedback on the review (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-07-01 15:39:26 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>The review includes nine short-term RCTs of PTSD prevention. A placebo comparison group was employed in each study, with one study having two medication arms (i.e. propranolol and gabapentin) (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>). Each study was published in English and supported by a grant and/or pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Three hundred and forty-five participants were included across the nine eligible studies. The average sample size was 38 and ranged from 20 (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>) to 64 (<LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>). Each study consisted of both males and females, with a mean age of approximately 40 years. Females accounted for 49% of the total proportion of the sample. The participants in each study were exposed to a range of trauma types, including assault (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>), injury (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), traffic or work accidents (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), terrorist attack (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>), cardiac surgery (<LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and septic shock (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>).</P>
<P>Participants who were exposed to a traumatic event were assessed according to DSM-IV criteria in six studies (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), and the additional three studies used specified structured or semi-structured measurements (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>Countries in which studies were conducted included the United States of America (e.g. Boston, San Diego) (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>), Germany (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and Israel (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>). Seven studies were single-centre trials (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), and two studies did not provide sufficient information to determine how many centres were recruited from (<LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>). Patient recruitment settings included intensive care unit (ICU) wards (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), trauma centres (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>), and hospital emergency departments (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The nine RCTs included four hydrocortisone studies (steroid) (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), three propranolol studies (beta-blocker) (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>) (with <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> investigating the anxiolytic anticonvulsant gabapentin) and single studies of temazepam (benzodiazepine) (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>) and escitalopram (SSRI) (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>). The duration of treatment for all pharmacological interventions ranged from a single dose of hydrocortisone (<LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>) to a 12-week intervention for escitalopram (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>). Dosages of hydrocortisone ranged from 40 mg/day (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>) to 140 mg/day (<LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), with propranolol administered in doses ranging from 120 mg/day (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>) to 240 mg/day (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>). The maximum dose of temazepam administered at bedtime was 30 mg, while a 10 mg table of escitalopram was administered twice daily in <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>. In <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>, the maximal daily dosage of gabapentin was 400 mg. The interventions were administered by psychologists (<LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>), psychiatrists (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), mental health professionals (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>), and nursing staff (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), as well as multi-disciplinary teams of investigators (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>).</P>
<P>Interventions were administered in the majority of studies within the first 12 hours after the traumatic event (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), and occurred during the course of the traumatic event in two studies (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>). Medication was only administered within two days after the trauma in <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>, and after an average of 14.3 days and 19.8 days in the case of the trials of temazepam (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>) and escitalopram (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>), respectively. Interventions occurred concurrently with administration of the study medication in some studies, including the stress hormones epinephrine and norepinephrine in patients who had undergone cardiac surgery with cardiopulmonary bypass (<LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and a course of antibiotics, fluid resuscitation, mechanical ventilation and norepinephrine in patients treated for septic shock (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>). Patients in <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> were also sedated with infusions of the benzodiazepine midazolam and the opioid fentanyl. Participants in <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK> received supportive counselling from the study nurse as appropriate during the course of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The dichotomous outcome of number of participants diagnosed with PTSD, as well as the secondary outcome of reduction in PTSD symptom severity, were assessed for each group using the Clinician-Administered PTSD Scale (CAPS) (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), the Post-Traumatic Stress Syndrome 10-Questions Inventory (PTSS-10Q-I) (<LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and the Structured Clinical Interview for DSM-IV (SCID-IV) (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The only study to use different measures of categorical PTSD diagnosis and symptom severity was <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>, in which the Comprehensive International Diagnostic Interview (CIDI) and the Posttraumatic Stress Disorder Checklist - Civilian Version (<LINK REF="REF-Weathers-2001" TYPE="REFERENCE">Weathers 2001</LINK>) were used for these purposes, respectively. The follow-up assessments ranged from as early as two weeks after the trauma (<LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>) to a median of 31 months after the event (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>).</P>
<P>Quality of life was assessed using the 36-item Medical Outcomes Study Short Form Survey (SF-36) (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>). Depression was assessed using the Center for Epidemiological Studies &#8211; Depression Scale (CES-D) (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>), as well as visual analogue scales (VAS) in <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>. <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK> was the only study in which anxiety symptoms was reported as being assessed, using visual analogue scales.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-07-02 09:08:01 +0100" MODIFIED_BY="Chris Champion">
<P>We excluded six studies from the review. Exclusions were based on study design (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>; <LINK REF="STD-Vaiva-2003" TYPE="STUDY">Vaiva 2003</LINK>), and sample characteristics (<LINK REF="STD-Davidson-2000" TYPE="STUDY">Davidson 2000</LINK>; <LINK REF="STD-Martenyi-2002" TYPE="STUDY">Martenyi 2002</LINK>; <LINK REF="STD-Martenyi-2006" TYPE="STUDY">Martenyi 2006</LINK>; <LINK REF="STD-Schelling-2004" TYPE="STUDY">Schelling 2004</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>Three studies are listed as ongoing: <LINK REF="STD-Zohar-2009" TYPE="STUDY">Zohar 2009</LINK>; <LINK REF="STD-Zohar-2010" TYPE="STUDY">Zohar 2010</LINK>; <LINK REF="STD-Zohar-2011b" TYPE="STUDY">Zohar 2011b</LINK> (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>Three trials were awaiting classification (<LINK REF="STD-Azad-2007" TYPE="STUDY">Azad 2007</LINK>; <LINK REF="STD-Marx-2006" TYPE="STUDY">Marx 2006</LINK>; <LINK REF="STD-Simon-2005" TYPE="STUDY">Simon 2005</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified three ongoing randomised, placebo-controlled studies of medication for the prevention of PTSD (<LINK REF="STD-Zohar-2009" TYPE="STUDY">Zohar 2009</LINK>; <LINK REF="STD-Zohar-2010" TYPE="STUDY">Zohar 2010</LINK>; <LINK REF="STD-Zohar-2011b" TYPE="STUDY">Zohar 2011b</LINK>). These RCTs are being conducted by the same group, and assess the effectiveness of hydrocortisone (<LINK REF="STD-Zohar-2011b" TYPE="STUDY">Zohar 2011b</LINK>), oxytocin (<LINK REF="STD-Zohar-2010" TYPE="STUDY">Zohar 2010</LINK>), and escitalopram (<LINK REF="STD-Zohar-2009" TYPE="STUDY">Zohar 2009</LINK>) in preventing the onset of PTSD. The investigators of these studies require that participants are exposed to a traumatic event, with exposure to trauma assessed within six hours after the traumatic event in two studies (<LINK REF="STD-Zohar-2010" TYPE="STUDY">Zohar 2010</LINK>; <LINK REF="STD-Zohar-2011b" TYPE="STUDY">Zohar 2011b</LINK>). All participants are required to be 18 years and older to meet study criteria. The CAPS will be employed for PTSD diagnosis and/or symptom severity assessment in both RCTs for which information on outcome assessment was available (<LINK REF="STD-Zohar-2009" TYPE="STUDY">Zohar 2009</LINK>; <LINK REF="STD-Zohar-2010" TYPE="STUDY">Zohar 2010</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>Placebo-controlled studies to be assessed for inclusion in the review, pending additional information, include a RCT on the efficacy of hydrocortisone in 92 high-risk survivors of cardiac surgery, with primary outcomes including immunologic markers, health care-related quality of life and PTSD (<LINK REF="STD-Azad-2007" TYPE="STUDY">Azad 2007</LINK>), as well as a flexible dose trial of 10 mg to 40 mg of paroxetine over 12 weeks in a recently deployed military veteran sample (<LINK REF="STD-Marx-2006" TYPE="STUDY">Marx 2006</LINK>). In addition, a 12-week placebo-controlled RCT of escitalopram for participants presenting with ASD criteria (A1 and A2 criteria and at least one additional criterion) after a traumatic injury that occurred in the prior three weeks, was discontinued (<LINK REF="STD-Simon-2005" TYPE="STUDY">Simon 2005</LINK>).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-01 15:43:58 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias using The Cochrane Collaboration's 'Risk of bias' tool for allocation concealment, blinding, incomplete outcome data, selective reporting and other potential sources of bias. We classified seven of the included studies as being at high risk for at least one type of bias (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Randomisation</HEADING>
<P>All included studies described the sequence generation as randomised. <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> employed random permutation blocking of participants, while <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK> utilised an equipoise-stratified randomisation scheme, in which participants were given the option of requesting not to be assigned to two of the four interventions assessed (prolonged exposure, cognitive therapy, escitalopram versus placebo, waiting list control). A central research pharmacy is described as setting up and maintaining the randomisation schedule in <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>. Group assignment was via a computer-generated randomisation list in <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> and <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>, while <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK> made reference to a predetermined randomisation schedule. <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK> employed a random number table to generate the randomisation schedule. We classified these seven studies as 'low' risk, with the risk of selection bias being designated as 'unclear' in the remaining studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Eight of the studies provided sufficient information to be considered at 'low' risk for selection bias resulting from failure to conceal the agents provided to the study participants. Medication was prepared by a central pharmacy in three studies (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>). In <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>, all syringes of hydrocortisone and placebo were labelled "study medication", while the medication and placebo were prepared by Lundbeck Pharmaceutical and supplied to clinicians by a research associate in <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>. <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> described the preparation of the study agents in vials by a study nurse who was not involved in the care of patients participating in the trial. <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK> described the use of identical pills/blister packs to conceal the allocation of group assignment from the study investigators. Hydrocortisone or placebo were given intravenously in numbered, identical intravenous bags in <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>. We assigned <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK> a rating of 'high' risk for selection bias, as no information regarding allocation concealment was provided in the study report.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<P>We classified all of the studies included in the review as being at 'low' risk of performance bias, as they either described themselves as "double-blinded" (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), or participants and personnel were explicitly described as blinded in the study report (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>), or through correspondence with the trial investigators (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessors</HEADING>
<P>We classified six of the studies included in the review as being at 'low' risk of detection bias, as they were explicitly described as blinded in the study report (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), or through correspondence with the trial investigators (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>). We classified <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK> as being at 'high' risk, as no information on blinding of the assessors was available for this study, while we rated the risk of bias as 'unclear' for two studies that described the study design as "double-blinded" (<LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies failed to provide sufficient information to determine whether the medication and placebo group were comparable with respect to drop-out proportions, or in terms of the demographic and clinical characteristics of those who withdrew (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>), garnering them a rating of 'unclear' risk. Substantially higher proportions of participants withdrew from the medication than the placebo groups in <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> (propanolol: 29.4%; gabapentin: 28.6%; placebo: 5.9%), <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK> (escitalopram: 26%; placebo: 60.9%) and <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK> (hydrocortisone: 40%; placebo: 20%), earning these studies a 'high' risk rating. Studies classified as being at 'low' risk included two RCTs that failed either to detect differences in attrition rates for the comparison groups, or in between-group comparisons of the characteristics of those who withdrew (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and one study in which no participants withdrew prior to follow-up (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>). We rated the remaining three studies as being at 'unclear' risk with regard to attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>It was unclear as to whether selective reporting took place in any of the included studies, either because the protocol was not available for the study (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), or because where the protocol was available, insufficient information was provided on the planned outcomes to be assessed (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>).<BR/>
</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-07-01 15:43:58 +0100" MODIFIED_BY="[Empty name]">
<P>Various methodological factors may have impacted on study findings, including the use of concurrent medication (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>) and psychological treatments during the study (<LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>); employment of invasive medical procedures in some trials (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>); failure to identify the index trauma through specification of the DSM-IV PTSD criterion A (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>); and industry funding of the trial (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>). We reserved ratings of 'high' risk of bias for three studies (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), with all others being classified as being at 'low' risk. In <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>, termination of follow-up was dependent on the clinical assessment of PTSD-related symptoms, with only 50% of cases followed up at the planned six-week assessment point. For both <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> and <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> participants receiving placebo required higher norepinephrine doses than participants on hydrocortisone. Although the difference in dosage of norepinephrine was not statistically significant in <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>, the investigators conceded that this may be an alternative explanation of higher PTSD onset in the placebo group, as previous studies have documented higher urinary excretion of norepinephrine in PTSD patients.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-07 15:09:46 +0100" MODIFIED_BY="[Empty name]">
<P>See: 'Summary of findings' for the main comparisons of propranolol versus placebo (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) and hydrocortisone versus placebo (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: Benzodiazepines versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Treatment efficacy: number of participants who developed post-traumatic stress disorder (PTSD)</HEADING>
<P>The single trial of temazepam reported a higher proportion of individuals on medication with a diagnosis of PTSD (6/11; 55%) at the final assessment than in the placebo group (3/11; 27%) (<LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>). A post hoc Fisher's exact test of the data provided by the investigators indicates that this difference was not statistically significant (odds ratio (OR) 3.03, P value = 0.387).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Treatment acceptability: number of participants who withdrew due to treatment-emergent side effects</HEADING>
<P>All patients completed the intervention and were assessed at follow-up in <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Reduction in PTSD symptoms</HEADING>
<P>Total symptom severity scores on the Clinician-Administered PTSD Scale (CAPS) decreased from 62.7 (standard deviation (SD) 24.1) at baseline in the medication group and 56.7 (SD 17.8) in the placebo group to 53.3 (SD 19.1) and 44.1 (SD 26.1) at the final assessment, respectively. There was no evidence that temazepam was more effective than placebo in reducing symptom severity (P value = 0.5; Hedges' g = 0.39, 95% confidence interval (CI) -0.48 to 1.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Reduction in comorbid symptom responses</HEADING>
<P>There were no data to determine the effect of medication on comorbid depression or anxiety symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 Quality of life</HEADING>
<P>There were no data to determine the effect of medication on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6 Functional impairment</HEADING>
<P>There were no data to determine the effect of medication on functional disability.</P>
<P>
<B>1.7 Side effects </B>
</P>
<P>There were no data to determine treatment-emergent side effects.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: Beta-blockers versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Treatment efficacy: number of participants who developed PTSD</HEADING>
<P>Evidence for the efficacy of the beta-blocker propranolol was assessed in three studies with 118 participants (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>). There was low quality evidence of an effect of medication on the number of patients diagnosed with PTSD at follow-up (risk ratio (RR) 0.62; 95% CI 0.24 to 1.59; number needed to treat to benefit (NNTB) = 14 to 27; see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Treatment acceptability: number of participants who withdrew due to treatment-emergent side effects</HEADING>
<P>There were insufficient data to conduct a meta-analysis for this outcome. No participants in <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> reported stopping medication during the first week of the two-week medication intervention due to treatment-emergent side effects. Neither <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK> nor <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK> provided data on the number of participants who withdrew during the treatment phase of the studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Reduction in PTSD symptoms</HEADING>
<P>We did not synthesise PTSD symptom severity outcome data provided for two of the propranolol randomised controlled trials (RCTs) (<LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>), due to evidence that the scores were not normally distributed. Taken individually, neither of these trials demonstrated an effect of medication. <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK> failed to detect a significant difference in mean score between the propranolol and placebo groups on the CAPS at either one month (mean (SD) 27.6 (15.7) versus 35.5 (21.5), respectively) or three months follow-up (21.1 (12.5) versus 20.5 (21.7), respectively). Similarly, no differences were observed for scores on the CAPS in participants receiving placebo or propranolol in <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>, after either one month (mean (SD) 28.5 (27.1) versus 28.5 (21.5), respectively) or three months (19 (25.8) versus 21.2 (26.1), respectively). Although <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> did observe an overall reduction in mean Posttraumatic Stress Disorder Checklist&#8211;Civilian Version (PCL-C) scores over time, these did not differ by comparison group (F &lt; 1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Reduction in comorbid symptom responses</HEADING>
<P>There were insufficient data to conduct a meta-analysis for this outcome. <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> reported that a generalised estimating equation (GEE) analysis of changes in depressive symptoms on the Center for Epidemiological Studies &#8211; Depression Scale (CES-D) over time failed to find an effect of propranolol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Quality of life</HEADING>
<P>There were no data to determine the effect of medication on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Functional impairment</HEADING>
<P>There were no data to determine the effect of medication on functional disability.</P>
<P>
<B>2.7 Side effects </B>
</P>
<P>
<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> reported that home nurse visits during the first three days of treatment did not detect symptoms, such as postural hypotension, which required the discontinuation of medication. <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK> reported minimal side effects for either hydrocortisone or placebo, with one incident of a fall (without serious injury) being attributed to the medication intervention. <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK> did not provide data on treatment-emergent side effects .</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: Selective serotonin reuptake inhibitors (SSRIs) versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>
<B>3.1 Treatment efficacy: number of participants who developed PTSD</B>
</P>
<P>There was no evidence in the single trial of escitalopram that medication was more effective than placebo in preventing the onset of PTSD, with 13/21 (61.9%) of participants receiving medication and 10/18 (55.6%) in the placebo group meeting diagnostic criteria at the five-month assessment (P value &gt; 0.05) (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>). Similar results were reported for the nine months post-trauma assessment (8/19 (42.1%) versus 8/17 (47.1%), respectively).</P>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Treatment acceptability: number of participants who withdrew due to treatment-emergent side effects</HEADING>
<P>Of the 23 participants randomised to 12 weeks of treatment with escitalopram or placebo, more than twice as many participants in the escitalopram arm (13; 56.5%) withdrew prior to the end of the study than in the placebo arm (6; 26.1%). These participants were not contacted to ascertain reasons for study withdrawal (personal communication, Dr. Shalev; 4 December 2013).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Reduction in PTSD symptoms</HEADING>
<P>There were insufficient data to conduct a meta-analysis for this outcome. Clinician-rated total symptom severity scores on the CAPS at the five-month assessment were similar in the escitalopram and placebo groups (mean (SD): 48.71 (29.63) versus 47.11 (20.13), respectively; Hedges' g = 0.06, 95% CI -0.58 to 0.7) and nine-month post-trauma assessments (47.16 (26.71) versus 45.71 (26.14), respectively; Hedges' g = 0.05, 95% CI -0.61 to 0.72). Similarly, no statistically significant differences were observed in comparisons across groups on the re-experiencing, hyperarousal and avoidance PTSD symptom cluster subscales of the CAPS. Finally, participants' own ratings of their PTSD symptoms, as assessed using the PTSD Symptom Scale &#8211; Self-Report Version (PSS-SR), did not differ by group at either time point.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Reduction in comorbid symptom responses</HEADING>
<P>There were no data to determine the effect of medication on comorbid depression or anxiety symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5 Quality of life</HEADING>
<P>There were no data to determine the effect of medication on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6 Functional impairment</HEADING>
<P>There were no data to determine the effect of medication on functional disability.</P>
<P>
<B>3.7 Side effects </B>
</P>
<P>There were no data to determine the effect of medication on treatment-emergent side effects .</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: Other medications versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Treatment efficacy: number of participants who developed PTSD</HEADING>
<P>We observed evidence for the efficacy of hydrocortisone in preventing the onset of PTSD in a combined sample of 165 participants across four studies (RR 0.17; 95% CI 0.05 to 0.56; see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The size of the medication effect translates to a number needed to treat to benefit (NNTB) of between seven and 13 patients. We deemed the quality of the evidence to be moderate. We conducted an additional post hoc analysis excluding <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> and <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>. We considered this necessary given the observation of potential bias introduced through greater administration of norepinephrine to septic shock and cardiac surgery patients receiving placebo than hydrocortisone in these respective RCTs. The combined analysis of PTSD prevention proportions excluding these studies still favoured the hydrocortisone intervention (RR 0.12; 95% CI 0.02 to 0.94).</P>
<P>The administration of the anticonvulsant agent gabapentin, in <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>, was associated with PTSD in two of 10 participants (20%) at four months after physical injury was sustained, compared to four of 16 participants (25%) on placebo, a statistically non-significant difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Treatment acceptability: number of participants who withdrew due to treatment-emergent side effects</HEADING>
<P>No data were provided on the proportion of participants who withdrew from treatment due to side effects in the majority of hydrocortisone trials (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>). <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK> observed that one of the 13 participants receiving hydrocortisone who discontinued between randomisation and the one-month assessment complained of dizziness. It was not possible to contact any of the remaining 20 participants (31.3%) across both comparison groups who withdrew prior to the three-month assessment. Although the number of participants who withdrew as a result of treatment-emergent side effects was not reported in the single trial of gabapentin (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>), the investigators noted that "subjective reporting by subjects indicated that study medications were well tolerated" (p927).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Reduction in PTSD symptoms</HEADING>
<P>Data were not available for this outcome for two of the hydrocortisone RCTs (<LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>). In addition, data from the PTSS-10Q-I at the three-month assessment in <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> was not normally distributed and therefore studies could not be pooled in the analysis. <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>, <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> and <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK> demonstrated the superiority of hydrocortisone compared to placebo in reducing PTSD symptom severity, with substantial differences being observed on the CAPS in <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK> after three months (mean of 19.4 versus 31.3, respectively), and on the Post-Traumatic Stress Syndrome 10-Questions Inventory (PTSS-10Q-I) after six months in <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> (median of 15.5 versus 25.5, respectively). <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK> reported a significant group difference favouring hydrocortisone at both two weeks and three months after a single dose administration (P value &lt; 0.25 and P value &lt; 0.2, respectively). Finally, <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> was not able to detect differences on the PTSS-10Q-I after a median of 31 months post-intervention between the hydrocortisone and control groups (median of 27 and 36 points, respectively).</P>
<P>
<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> reported that symptoms of PTSD did not decline over time in the gabapentin compared to the placebo group. No additional data on this outcome were provided in the study report.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Reduction in comorbid symptom responses</HEADING>
<P>There were insufficient data to conduct a meta-analysis of the effect of hydrocortisone or gabapentin on comorbid depression or anxiety symptoms. Based on a series of repeated-measures ANCOVA analyses of outcomes assessed at one and three months post-injury, <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK> reported that participants treated with hydrocortisone demonstrated reduced symptoms of depression on the CES-D compared to the control group (F(1,18) = 7.7, P value = 0.01) over time. Rates of major depressive disorder (MDD) assessed using the Comprehensive International Diagnostic Interview (CIDI) in <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK> were similar in the gabapentin and placebo groups four months after the traumatic event (gabapentin: 2/10; placebo: 4/16).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5 Quality of life</HEADING>
<P>There were insufficient data to conduct a meta-analysis for this outcome. <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK> reported improvements in quality of life assessed using the SF-36 scale over multiple time points (F(1,18) = 5.3, P value = 0.03). Similarly, <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> reported improvements in the hydrocortisone group compared to placebo on the SF-36 physical and mental summary scores, with statistically significant increases observed in the medication group on seven of the eight subscales of this instrument.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.6 Functional impairment</HEADING>
<P>There were no data to determine the effect of either hydrocortisone or gabapentin on functional disability.</P>
<P>
<B>4.7 Side effects </B>
</P>
<P>There were no differences in the number of side effects between the medication and placebo groups in the trials that reported these. With regard to hydrocortisone, <LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK> reported that one individual receiving medication experienced an intestinal haemorrhage that was treated conventionally (personal communication); treatment was reported in <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK> as being "well tolerated with no noticeable side effects" (p800); <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK> declared the number of patients in their study as being "too small to detect these [side] effects" (p282); and data on side effects were not reported in <LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>. Information on side effects was not reported for the trial of gabapentin, though all medications tested in this study were described as being very well tolerated, based on subjective patient report (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity</HEADING>
<P>We found no evidence of heterogeneity for trials of hydrocortisone (Chi² = 0.43, P value = 0.93, I² = 0%, see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and propranolol (Chi² = 0.18, P value = 0.91, I² = 0%, see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), when investigating the efficacy of treatment in preventing PTSD onset.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>There were insufficient studies to conduct a subgroup analysis (fewer than 10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Use of an intention-to-treat (ITT) versus observed cases sample in calculating response to treatment</HEADING>
<P>Effect estimates for the hydrocortisone versus placebo comparisons were similar, regardless of whether the effect estimate was calculated based on the proportion of participants who developed PTSD at follow-up out of the ITT (RR 0.17; 95% CI 0.05 to 0.56) or observed cases sample (RR 0.20; 95% CI 0.06 to 0.64) <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>. We observed a similar finding with respect to the propranolol versus placebo comparison (ITT sample: RR 0.62; 95% CI 0.24 to 1.59; observed cases sample: RR 0.73; 95% CI 0.29 to 1.84) <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>The greatest number of studies in any comparison in this review was equal to four (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). We regarded this as insufficient to warrant conducting qualitative or quantitative tests that would inform the assessment of publication bias.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-07-07 15:11:01 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-07-03 12:31:16 +0100" MODIFIED_BY="[Empty name]">
<P>The largest number of randomised controlled trials (RCTs) investigating the effectiveness of medication in preventing the onset of post-traumatic stress disorder (PTSD) are for the steroid hydrocortisone and the beta-blocker propranolol. We observed evidence of moderate quality for the efficacy of hydrocortisone in preventing PTSD in four studies following exposure to a traumatic event (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Assuming a baseline onset of PTSD of 10% to 20% for studies that assessed participants a median of four and a half months after trauma exposure, this translates to having to treat seven to 13 patients with hydrocortisone in order for the agent to prevent the onset of PTSD in one patient. A synthesis of the low quality results from three RCTs of propranolol did not support the ability of this agent to prevent the onset of PTSD (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). This was despite promising findings from a series of three open-label studies employing symptom provocation paradigms, in which the repeated administration of propranolol was associated with reduced numbers of participants diagnosed with PTSD (<LINK REF="REF-Brunet-2011" TYPE="REFERENCE">Brunet 2011</LINK>). The solitary trials of escitalopram, temazepam and gabapentin failed to demonstrate that short-term interventions employing these medications affect the onset of PTSD.</P>
<P>Where provided, drop-outs due to side effects of medication were comparable between the medication and placebo interventions, suggesting that the agents were well tolerated. This may be due to a variety of factors, including (a) the short duration of treatment for many of the trials of hydrocortisone and propranolol in particular, with <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>, for instance, administering hydrocortisone at a single session, (b) the fact that treatment often took place at least partly in a controlled environment, such as within trauma centres, where medication response and adherence could be closely monitored, and dosages adjusted accordingly, and (c) that dosages were in the low range for agents that were administered over extended periods, such as the administration of 20 mg/day of escitalopram over 12 weeks (<LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>). Conclusions that medications are well tolerated should be regarded as preliminary, however, given that data on treatment-emergent side effects were often not reported, regardless of whether these led to study withdrawal.</P>
<P>Reductions in PTSD symptom severity were observed in three of the four studies of hydrocortisone, with null findings reported for all of the propranolol studies, as well as for the trials of escitalopram, gabapentin and temazepam. A narrative review indicates that hydrocortisone may improve quality of life (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and possibly reduce symptoms of depression (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>), in individuals who have been treated within 12 hours of the traumatic event.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-07-01 15:55:44 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Completeness of evidence</HEADING>
<P>Reviews of the body of evidence for pharmacotherapy of PTSD have concluded that selective serotonin reuptake inhibitors (SSRIs) are first-line medication agents for the treatment of PTSD (<LINK REF="REF-Ipser-2011" TYPE="REFERENCE">Ipser 2011</LINK>), with promising findings for the selective noradrenergic reuptake inhibitor (SNRI) venlafaxine and the atypical antipsychotic risperidone. Despite a comprehensive search, we were only able to find a single trial testing the efficacy of a SSRI medication (escitalopram) in preventing PTSD. The efficacy of other medication classes that are frequently considered for treating PTSD in the prevention of the onset of this disorder, such as the tricyclic antidepressants (TCAs) and mono-amine oxidase inhibitors (MAOIs), has also not been investigated.</P>
<P>Limited data were available to assess the effect of medication on comorbid symptoms of depression and anxiety, as well as quality of life. None of the included studies assessed post-treatment changes in functional ability. Additionally, the paucity of studies and missing data hampered our ability to assess the degree to which methodological differences between studies might have systematically influenced differences observed in the primary treatment outcome. Accordingly, our conclusions are limited to a small range of drugs and many of our review questions remain unanswered.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Applicability of evidence</HEADING>
<P>The outcomes of this review may be generalisable to a diverse range of settings. Studies were conducted in the United States of America (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Mellman-2002" TYPE="STUDY">Mellman 2002</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>), Germany (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>), and Israel (<LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), in both out- and inpatient settings, with interventions targeting both males and females across a wide age range. Differences in treatment delivery, as well as the background and training of study investigators and outcome assessors, increases the likelihood that the findings of this review are applicable to a range of developed and developing nation contexts.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-07-07 15:11:01 +0100" MODIFIED_BY="[Empty name]">
<P>We included nine studies with 345 participants in the review. Seven of the included RCTs possessed a high risk of bias related to at least one aspect of study design, with weaknesses most commonly observed with respect to allocation concealment and differential attrition in the medication and control groups. In addition, the effects of medication may have been confounded in a number of studies of patients in emergency care, trauma centre and surgery settings who were receiving other medications concurrently with the intervention to prevent PTSD (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>).</P>
<P>We judged the evidence for the efficacy of hydrocortisone in preventing PTSD to be of moderate quality (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Accordingly, further research is likely to have an important impact on our confidence in the estimate of this agent's treatment effect, and may even change that estimate. The low quality rating of the corresponding estimate for propranolol indicates that the size of the non-significant effect of this agent in preventing PTSD is likely to change. This reflects shortcomings in the data set contributing to this outcome, including the small number of studies, missing data and small samples included in these studies. These shortcomings are likely to be equally pertinent with respect to the null findings for the trials of escitalopram, temazepam and gabapentin. Another potential explanation for the observation that the outcomes assessed in this review appeared to be relatively insensitive to the effects of medications may be the relatively low background rate of PTSD in the samples that constituted the evidence base for this review, as discerned from the proportion of individuals in the placebo groups who were diagnosed with chronic PTSD (31.6%).</P>
<P>The absence of any evidence that the benzodiazepine temazepam prevents PTSD or reduces PTSD symptoms is consistent with prior negative findings reported for a non-randomised controlled trial of clonazepam or alprazolam (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>). Nevertheless, the limitations of the temazepam study (its small size (N = 21), the fact that assessments of PTSD were conducted less than three months after the trauma event, that in one half of the cases the intervention was terminated when clinical judgement indicated the initiation of other medication treatment, and that participants were not required to endorse the Diagnostic and Statistical Manual (DSM-IV) criterion A for PTSD) suggest that conclusive evidence regarding the efficacy of benzodiazepines in preventing PTSD awaits further controlled studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>We minimised overall bias in this review process through conducting an extensive search for studies meeting rigorous methodological inclusion criteria, and through repeated attempts to obtain missing data from the trial investigators. Nevertheless, the small number of eligible studies compromised our ability to assess the extent to which biases, with respect to which studies were published, might have influenced the review findings. Furthermore, the post hoc addition of propranolol may have also introduced bias as a result of the small number of trials we found, and may be susceptible to publication bias, though this was not tested for. It is also noteworthy that all seven included RCTs that provided information on the number of sites recruited from were classified as single-site studies. Single-site RCTs may provide biased estimates of treatment effect, as a recent meta-analysis demonstrated that the size of these estimates are larger than those observed with multi-centre trials (<LINK REF="REF-Dechartres-2011" TYPE="REFERENCE">Dechartres 2011</LINK>).<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>The conclusions of the review are only partially consistent with those arrived at by other systematic reviews on the effects of pharmacological interventions to prevent PTSD (<LINK REF="REF-Bisson-2010" TYPE="REFERENCE">Bisson 2010</LINK>; <LINK REF="REF-Sones-2011" TYPE="REFERENCE">Sones 2011</LINK>). For instance, <LINK REF="REF-Bisson-2010" TYPE="REFERENCE">Bisson 2010</LINK> determined that evidence for the effectiveness of hydrocortisone and various other medications was inconclusive, with cognitive behavioural techniques identified as the most beneficial intervention to prevent PTSD. Similar conclusions were reached in a review conducted by <LINK REF="REF-Forneris-2013" TYPE="REFERENCE">Forneris 2013</LINK>. <LINK REF="REF-Sones-2011" TYPE="REFERENCE">Sones 2011</LINK>, on the other hand, suggested that several pharmacological interventions for PTSD prevention might be of benefit, including propranolol, morphine, glucocorticoids and SSRIs, based on a review of RCTs and open-label studies. These studies differed from the current review in that they included data from preventative studies containing patients diagnosed with PTSD. The finding of minimal effect of the benzodiazepine temazepam in reducing the onset of PTSD following trauma exposure is consistent with an earlier study (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>), in which the sequential administration of clonazepam (mean 2.7 mg/day) or alprazolam (mean 2.5 mg/day) to emergency department trauma-exposed patients, on average within a week after trauma exposure, failed to reduce PTSD symptoms, as assessed using the Mississippi Rating Scale for Combat-Related PTSD-civilian version.</P>
<P>Other Cochrane reviews on interventions to prevent PTSD have been conducted, with a focus on single-session psychological debriefing interventions (<LINK REF="REF-Rose-2002" TYPE="REFERENCE">Rose 2002</LINK>), multiple-session early psychological interventions (<LINK REF="REF-Roberts-2010" TYPE="REFERENCE">Roberts 2010</LINK>), and psychosocial interventions (<LINK REF="REF-De-Silva-2009" TYPE="REFERENCE">De Silva 2009</LINK>; <LINK REF="REF-Pe_x00f1_alba-2009" TYPE="REFERENCE">Peñalba 2009</LINK>). This review represents an extension of this body of work, with a specific focus on pharmacological interventions for the prevention of PTSD development.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-07-03 12:27:24 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-07-03 12:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>The only agent for which there was preliminary evidence of efficacy in the prevention of post-traumatic stress disorder (PTSD) following trauma exposure was hydrocortisone. Absence of evidence for the efficacy of propranolol, escitalopram, gabapentin and temazepam in preventing PTSD or reducing symptom severity argues against their routine use for this indication. This is particularly the case given the low quality of the evidence for propranolol, resulting partly from methodological shortcomings that were also apparent in single trials of gabapentin and temazepam. Although the limited data on treatment-emergent side effects suggest that all of the medications assessed were well tolerated by patients, this should be balanced against the additional complications in administering these medications in emergency department and trauma clinic settings (including possible interactions with other medications being administered to treat the trauma). Based on these considerations, and pending further research, we believe there is not sufficient evidence at this stage to endorse any medication for the prevention of PTSD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>This review highlights the need for additional randomised controlled trials (RCTs) to evaluate the effectiveness of medications to prevent PTSD, including those agents assessed in this review (hydrocortisone, propranolol, escitalopram, gabapentin and temazepam). Methodological limitations of the studies included in this review, and formalised using the GRADE approach, include small sample size, no description of methods to conceal medication allocation adequately and differences in attrition rate observed between comparison groups. Where possible, these limitations should be addressed in future studies.</P>
<P>RCTs of medication to prevent PTSD are challenging on many fronts, including the unique ethical considerations involved in medicating individuals prior to presentation with a trauma-associated psychiatric diagnosis, as well as difficulties in recruiting participants from this patient population. By pooling participants across multiple centres, future studies would ensure sufficient power to investigate the effect of a number of factors that may affect treatment response, including the optimal clinical window after trauma exposure for the initiation of treatment, dosage and duration of treatment, and the moderating effect of clinical (e.g. trauma type) and demographic factors (e.g. age, gender, ethnicity) in predicting response to medication.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-03 14:17:20 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Drs. Schelling, Mellman, Delahanty, Shalev, Hoge and Cohen (on behalf of <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>) for responding to requests for additional data for the update of the review. We are also grateful to Dr. Nandi Siegfield and Dr. Tamara Kredo for their continuous support.</P>
<P>
<U>CRG Funding Acknowledgement</U>:<BR/>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Depression, Anxiety and Neurosis Group. </P>
<P>
<U>Disclaimer</U>:<BR/>The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Potential conflicts of interest for individual review authors</B>
</P>
<P>Taryn Amos has no known conflict of interest outside of her employment by the MRC Unit on Anxiety and Stress Disorders.</P>
<P>Jonathan Ipser has no known conflict of interest.</P>
<P>Dan Stein has received research grants and/or consultancy honoraria from AstraZeneca, Eli-Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo and Wyeth. He has participated in a number of ongoing studies and has presented data from some of these studies on behalf of the sponsoring companies.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-07-01 16:00:31 +0100" MODIFIED_BY="[Empty name]">
<P>Jonathan Ipser compiled the background and methods sections of the protocol, and assisted in making changes to the review in response to editorial feedback. Dan Stein assisted in this process and also served as a co-ordinator for the protocol. Taryn Amos compiled the original version of the review, including the data analysis section.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-07-03 12:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>We removed the third objective stated in the protocol, namely to assess whether depression is a predictor of treatment response in the prevention of PTSD, from the review, as it taps into risk rather than preventative factors for the onset of PTSD.</P>
<P>The timing of the outcome event was not made explicit in the protocol for the review. It has now been stated in the text that for studies that assessed outcomes at multiple time points (<LINK REF="STD-Delahanty-2012" TYPE="STUDY">Delahanty 2012</LINK>; <LINK REF="STD-Hoge-2012" TYPE="STUDY">Hoge 2012</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Shalev-2012" TYPE="STUDY">Shalev 2012</LINK>; <LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>; <LINK REF="STD-Zohar-2011a" TYPE="STUDY">Zohar 2011a</LINK>), we synthesised data at the first time point that was consistent with chronic PTSD, in which the assessment occurred after at least three months after the index traumatic event.</P>
<P>The original protocol imposed an age range criterion for eligible studies of 18 to 65 years. We decided to remove the restriction on the maximum age of the sample, as this allowed us to include data from a number of studies that would otherwise have been excluded (<LINK REF="STD-Schelling-2001" TYPE="STUDY">Schelling 2001</LINK>; <LINK REF="STD-Weis-2006" TYPE="STUDY">Weis 2006</LINK>). While medications might be expected to metabolise at a different rate in paediatric samples, there is no evidence that PTSD is less likely to occur in populations over 65 years of age than in middle age, or that the effects of medication in this older age group will differ substantially from younger adults.</P>
<P>The original protocol described comparisons between medication and placebo arms, as well as alternative 'standard' medication therapy. The review was restricted to placebo-controlled studies, as we only found one placebo-controlled RCT that included an active medication control arm (<LINK REF="STD-Stein-2007" TYPE="STUDY">Stein 2007</LINK>).</P>
<P>We have moved treatment acceptability from a secondary to a primary outcome for this review. This is in keeping with recommendations within the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> that primary outcomes of a review should include negative as well as positive outcomes (Section 4.5) (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>), and in recognition that side effects are particularly salient when considering prophylactic studies.</P>
<P>Clinical response to treatment was included as a secondary outcome in the original protocol, as assessed using the Clinical Global Impressions Scale - Improvement Item (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) or related scales. In light of the tendency of studies to report reductions in PTSD symptom severity instead of more general responses to treatment, we have instead replaced this outcome in the review with reductions in PTSD symptom severity (as assessed using scales such as the CAPS and the PTSS-10).</P>
<P>Heterogeneity of treatment response and symptom severity was not assessed by means of Deeks' stratified test of heterogeneity (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>), as planned in the original protocol, nor was this assessed visually from the forest plot of relative risk, given the small number of studies. We did not conduct planned subgroup analyses to assess the extent to which the primary outcomes were affected by (a) source of trial funding, (b) whether trials were conducted at a single centre or across multiple centres, or (c) whether depressed individuals were included in the sample, for the same reason.</P>
<P>We have expanded the list of medication categories under <LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK> to include beta-blockers, to account for the large number of studies assessing the efficacy of propranolol in preventing the onset of PTSD.</P>
<P>In the protocol it was stated that treatment efficacy of medication in preventing PTSD would be determined using the number of cases diagnosed according to DSM criteria. In the review we decided to broaden this outcome to include data from studies assigning a probable diagnosis of PTSD using the Posttraumatic Stress Symptom 10 Questionnaire Inventory (PTSS-10), as this measure has demonstrated moderate to high (77%) sensitivity and excellent (97.5%) specificity in diagnosing clinically confirmed cases of PTSD (<LINK REF="REF-Weisaeth-1989" TYPE="REFERENCE">Weisaeth 1989</LINK>).</P>
<P>The small number of participants in the included studies in this review means that evidence of outcome data that are not normally distributed might be particularly problematic. There was no procedure in place in the protocol to address skewed data. We have now added a description of such a procedure to the data synthesis component of the methods section. In addition, we have indicated that we intend to obtain individual patient data (where possible) for the purpose of normalising the data by means of log transformation techniques in future updates of the review.</P>
<P>We computed Hedges' g effect size estimate and 95% confidence intervals where study results for the PTSD symptom reduction outcome were described as part of a narrative review. Although not originally part of the protocol, we added this to the review to aid interpretability, as per the recommendation provided as part of editorial feedback on a draft version of the review.</P>
<P>We added to the review a sensitivity analysis to detect the influence of using the ITT sample as the denominator in calculating risk ratios for the primary outcome of PTSD prevention, rather than the observed cases sample that was reported in the study publications, based on feedback provided by an anonymous reviewer of the manuscript for the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-03 12:45:38 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Delahanty-2012" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Delahanty 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Delahanty DL, Gabert-Quillen C, Ostrowski SA, Nugent NR, Fischer B, Morris A, et al</AU>
<TI>The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial</TI>
<SO>CNS Spectrums</SO>
<YR>2013</YR>
<VL>18</VL>
<PG>103-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-12 13:43:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delahanty DL, Ostrowski S, Nugent N, Gabert C, Fallon W</AU>
<TI>Hydrocortisone as a secondary intervention to prevent subsequent PTSD symptoms [conference abstract]</TI>
<SO>Psychosomatic Medicine [abstracts from the 69th Annual Meeting of the American Psychosomatic Society; 2011 Mar 9-12; San Antonio, TX United States]</SO>
<YR>2011</YR>
<VL>73</VL>
<NO>3</NO>
<PG>A107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoge-2012" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hoge 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoge EA, Worthington JJ, Nagurney JT, Chang Y, Kay EB, Feterowski CM, et al</AU>
<TI>Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery</TI>
<SO>CNS Neuroscience and Therapeutics</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-03-12 11:01:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-12 11:01:10 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00158262"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mellman-2002" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Mellman 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mellman TA, Bustamante V, Daniella D, Fins AI</AU>
<TI>Hypnotic medication in the aftermath of trauma</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>12</NO>
<PG>1183-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mellman TA, Byers PM, Augenstein JS</AU>
<TI>Pilot evaluation of hypnotic medication during acute traumatic stress response</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>3</NO>
<PG>563-9</PG>
<IDENTIFIERS MODIFIED="2013-03-06 07:07:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitman-2002" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Pitman 2002" YEAR="">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, et al</AU>
<TI>Pilot study of secondary prevention of posttraumatic stress disorder with propranolol</TI>
<SO>Biological Psychiatry</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schelling-2001" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Schelling 2001" YEAR="">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Briegal J, Roozendaal B, Stoll C, Rothenhausler H-B, Kapfhammer HP</AU>
<TI>The effect of stress doses of hydrocortisone during septic shock on post traumatic stress disorder in survivors</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>978-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Stoll C, Kapfhammer HP, Rothenhäusler HB, Krauseneck T, Durst K, et al</AU>
<TI>The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors</TI>
<SO>Critical Care Medicine</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>12</NO>
<PG>2678-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 12:48:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Stoll C, Wichmann A, Haller M, Schuffel W, Briegel J</AU>
<TI>The effect of hydrocortisone (HC) during septic shock on incidence and intensity of post-traumatic stress disorder (PTSD) in long term survivors</TI>
<SO>Critical Care Medicine</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>1</NO>
<PG>131A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shalev-2012" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Shalev 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-08 07:55:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galatzer-Levy IR, Ankri Y, Freedman S, Israeli-Shalev Y, Roitman P, Gilad M, et al</AU>
<TI>Early PTSD symptom trajectories: persistence, recovery, and response to treatment: results from the Jerusalem trauma outreach and prevention study (J-TOPS)</TI>
<SO>PloS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>8</NO>
<PG>e70084</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-12 11:03:02 +0000" MODIFIED_BY="Jonathan Ipser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shalev AY, Ankri Y, Israeli-Shalev Y, Peleg T, Adessky R, Freedman S</AU>
<TI>Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2012</YR>
<VL>69</VL>
<NO>2</NO>
<PG>166-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shalev AY, Ankri YL, Peleg T, Israeli-Shalev Y, Freedman S</AU>
<TI>Barriers to receiving early care for PTSD: results from the Jerusalem trauma outreach and prevention study</TI>
<SO>Psychiatric Services</SO>
<YR>2011</YR>
<VL>62</VL>
<PG>765&#8211;73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-03-12 11:03:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-12 11:03:30 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00146900"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2007" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Stein 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein MB, Kerridge C, Dimsdale JE, Hoyt DB</AU>
<TI>Pharmacotherapy to prevent PTSD: results from a randomised controlled proof-of-concept trial in physically injured patients</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>6</NO>
<PG>923-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weis-2006" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Weis 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weis F, Kilger E, Roozendaal B, De Quervain D-F, Lamm P, Schmidt M, et al</AU>
<TI>Stress doses of hydrocortisone reduce chronic stress symptoms and improve health-related quality of life in high-risk patients after cardiac surgery: a randomized study</TI>
<SO>Cardiopulmonary Support and Physiology</SO>
<YR>2006</YR>
<VL>131</VL>
<PG>277-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zohar-2011a" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Zohar 2011a" YEAR="2011">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zohar J, Yahalom H, Kozlovsky N, Cwikel-Hamzany S, Matar MA, Kaplan Z, et al</AU>
<TI>High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2011</YR>
<VL>21</VL>
<PG>796&#8211;809</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2000" MODIFIED="2012-04-12 09:35:47 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2000" YEAR="">
<REFERENCE MODIFIED="2012-04-04 11:37:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson J, Londborg P, Pearlstein T, Rothbaum B, Brady K, Farfel G</AU>
<TI>Sertraline and posttraumatic stress disorder: results of 24 weeks of open-label sertraline followed by a 28-week discontinuation study</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>S349</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelpin-1996" MODIFIED="2013-11-25 05:56:00 +0000" MODIFIED_BY="[Empty name]" NAME="Gelpin 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-11-25 05:56:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY</AU>
<TI>Treatment of recent trauma survivors with benzodiazepines: a prospective study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>9</NO>
<PG>390-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martenyi-2002" MODIFIED="2012-09-05 14:27:12 +0100" MODIFIED_BY="[Empty name]" NAME="Martenyi 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-05 14:27:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A</AU>
<TI>Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>181</VL>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martenyi-2006" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Martenyi 2006" YEAR="">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC</AU>
<TI>Fluoxetine versus placebo in posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>3</NO>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Soldatenkova V</AU>
<TI>Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled randomized clinical trial</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>5</NO>
<PG>340-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schelling-2004" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Schelling 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Kilger E, Roozendaal B, de Quervain DJ-F, Briegel J, Dagge A, et al</AU>
<TI>Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study</TI>
<SO>Society of Biological Psychiatry</SO>
<YR>2004</YR>
<VL>55</VL>
<PG>627&#8211;33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaiva-2003" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Vaiva 2003" YEAR="">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, et al</AU>
<TI>Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma</TI>
<SO>Society of Biological Psychiatry</SO>
<YR>2003</YR>
<VL>54</VL>
<PG>947-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Azad-2007" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Azad 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Azad S, Shelling G</AU>
<TI>Influence of Hydrocortisone on Immunologic Markers and Health Care Related Quality of Life in Patients After Cardiac Surgery</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00490828</SO>
<YR>2007 (accessed 12 March 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauer D, Weis F, Campolongo P, Schopp M, Beiras-Fernandez A, Strewe C, et al</AU>
<TI>Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: relationship to early cognitive dysfunction and late depression</TI>
<SO>Reviews in the Neurosciences</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>5-6</NO>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-11 12:16:39 +0000" MODIFIED_BY="Jonathan Ipser">
<IDENTIFIER MODIFIED="2013-12-11 12:16:39 +0000" MODIFIED_BY="Jonathan Ipser" TYPE="CTG" VALUE="NCT00490828"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Marx-2006" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Marx 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Marx CE</AU>
<TI>Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00560612</SO>
<YR>2007 (accessed 12 March 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-11 12:21:45 +0000" MODIFIED_BY="Jonathan Ipser">
<IDENTIFIER MODIFIED="2013-12-11 12:21:45 +0000" MODIFIED_BY="Jonathan Ipser" TYPE="CTG" VALUE="NCT00560612"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Simon-2005" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Simon 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Simon NM</AU>
<TI>SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00114374</SO>
<YR>2005 (accessed 12 March 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-11 12:29:59 +0000" MODIFIED_BY="Jonathan Ipser">
<IDENTIFIER MODIFIED="2013-12-11 12:29:59 +0000" MODIFIED_BY="Jonathan Ipser" TYPE="CTG" VALUE="NCT00114374 "/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Zohar-2009" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Zohar 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zohar J</AU>
<TI>PTSD Prevention Using Escitalopram</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00300313</SO>
<YR>2006 (accessed 12 March 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-11 12:55:14 +0000" MODIFIED_BY="Jonathan Ipser">
<IDENTIFIER MODIFIED="2013-12-11 12:55:14 +0000" MODIFIED_BY="Jonathan Ipser" TYPE="CTG" VALUE="NCT00300313"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Zohar-2010" MODIFIED="2014-03-12 12:21:53 +0000" MODIFIED_BY="[Empty name]" NAME="Zohar 2010" YEAR="">
<REFERENCE MODIFIED="2014-03-12 12:21:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zohar J</AU>
<TI>The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01039766</SO>
<YR>2009</YR>
<NO>accessed 12 March 2014</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-11 10:11:50 +0000" MODIFIED_BY="Jonathan Ipser">
<IDENTIFIER MODIFIED="2013-12-11 10:11:50 +0000" MODIFIED_BY="Jonathan Ipser" TYPE="CTG" VALUE="NCT01039766"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zohar-2011b" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Zohar 2011b" YEAR="">
<REFERENCE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zohar J</AU>
<TI>Efficacy of Single Dose IV Hydrocortisone in Post Traumatic Stress Disorder (PTSD) Prevention</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00855270</SO>
<YR>2009 (accessed 12 March 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-12 12:23:13 +0000" MODIFIED_BY="Jonathan Ipser" PRIMARY="NO" TYPE="OTHER">
<AU>Zohar J</AU>
<TI>Randomized placebo-controlled trial of hydrocortisone in PTSD prophylaxis</TI>
<SO>http://projectreporter.nih.gov; Project Number: 4R01MH086570-03 (accessed 12 March 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-03-12 12:12:07 +0000" MODIFIED_BY="Jonathan Ipser">
<IDENTIFIER MODIFIED="2014-03-12 12:12:07 +0000" MODIFIED_BY="Jonathan Ipser" TYPE="OTHER" VALUE=" NCT00855270; http://projectreporter.nih.gov/; Project Number:4R01MH086570-03"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-03 12:45:38 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-03 12:45:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-APA-1994" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1961" NAME="Beck 1961" TYPE="JOURNAL_ARTICLE">
<AU>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J</AU>
<TI>An inventory for measuring depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1961</YR>
<VL>4</VL>
<PG>561-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besnard-2012" MODIFIED="2014-07-01 12:57:19 +0100" MODIFIED_BY="[Empty name]" NAME="Besnard 2012" TYPE="JOURNAL_ARTICLE">
<AU>Besnard A, Caboche J, Laroche S</AU>
<TI>Reconsolidation of memory: a decade of debate</TI>
<SO>Progress in Neurobiology</SO>
<YR>2012</YR>
<VL>99</VL>
<NO>1</NO>
<PG>61-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bisson-2010" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Bisson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bisson J</AU>
<TI>Post-traumatic stress disorder</TI>
<SO>Clinical Evidence</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>1-62</PG>
<PB>BMJ Publishing Group Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blake-1995" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Blake 1995" TYPE="JOURNAL_ARTICLE">
<AU>Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al</AU>
<TI>The development of a clinician-administered PTSD scale</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>1</NO>
<PG>75-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bremner-2004" NAME="Bremner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bremner JD, Vermetten E</AU>
<TI>Neuroanatomical changes associated with pharmacotherapy in posttraumatic stress disorder</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>2004</YR>
<VL>1032</VL>
<PG>154-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brewin-2000" NAME="Brewin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brewin CR, Andrews B, Valentine JD</AU>
<TI>Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2000</YR>
<VL>68</VL>
<NO>5</NO>
<PG>748-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunet-2008" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Brunet 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK</AU>
<TI>Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2008</YR>
<VL>42</VL>
<PG>503&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunet-2011" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Brunet 2011" TYPE="JOURNAL_ARTICLE">
<AU>Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, et al</AU>
<TI>Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<PG>547-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bryant-2003" MODIFIED="2013-02-06 13:22:40 +0000" MODIFIED_BY="[Empty name]" NAME="Bryant 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bryant RA</AU>
<TI>Early predictors of posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2003</YR>
<VL>53</VL>
<PG>789-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Jong-2001" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="de Jong 2001" TYPE="JOURNAL_ARTICLE">
<AU>de Jong JTVM, Komproe IH, Van Ommeren M, Masri MEI, Araya M, Khaled N, et al</AU>
<TI>Lifetime events and posttraumatic stress disorder in 4 postconflict settings</TI>
<SO>American Medical Association</SO>
<YR>2001</YR>
<VL>286</VL>
<PG>555-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Quervain-2009" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="de Quervain 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Quervain DJF, Aerni A, Schelling G, Roozendaal B</AU>
<TI>Glucocorticoids and the regulation of memory in health and disease</TI>
<SO>Frontiers in Neuroendocrinology</SO>
<YR>2009</YR>
<VL>30</VL>
<PG>358-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Silva-2009" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="De Silva 2009" TYPE="COCHRANE_REVIEW">
<AU>De Silva M, MacLachlan M, Devane D, Desmond D, Gallagher P, Schnyder U, et al</AU>
<TI>Psychosocial interventions for the prevention of disability following traumatic physical injury</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-02-27 07:02:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-27 07:02:03 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006422.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dechartres-2011" MODIFIED="2014-04-08 07:58:38 +0100" MODIFIED_BY="[Empty name]" NAME="Dechartres 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P</AU>
<TI>Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>155</VL>
<PG>39-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG</AU>
<TI>Effect measures for meta-analysis of trials with binary outcomes</TI>
<SO>Systematic Reviews in Health Care: Meta-analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2002" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ</AU>
<TI>Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1575-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Del-Re-2013" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Del Re 2013" TYPE="COMPUTER_PROGRAM">
<AU>Del Re, AC</AU>
<TI>compute.es: Compute Effect Sizes. R package version 0.2-2</TI>
<YR>2013</YR>
<PB>http://cran.r-project.org/web/packages/compute.es</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne ER, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erbes-2007" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Erbes 2007" TYPE="JOURNAL_ARTICLE">
<AU>Erbes C, Westermeyer J, Engdahl B, Johnsen E</AU>
<TI>Post-traumatic stress disorder and service utilization in a sample of service members from Iraq and Afghanistan</TI>
<SO>Military Medicine</SO>
<YR>2007</YR>
<VL>172</VL>
<NO>4</NO>
<PG>359-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forneris-2013" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Forneris 2013" TYPE="JOURNAL_ARTICLE">
<AU>Forneris CA, Gartlehner G, Brownley KA, Gaynes BN, Sonis J, Coker-Schwimmer E, et al</AU>
<TI>Interventions to prevent post-traumatic stress disorder: a systematic review</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2013</YR>
<VL>44</VL>
<NO>6</NO>
<PG>635&#8211;50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillies-2012" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gillies 2012" TYPE="COCHRANE_REVIEW">
<AU>Gillies D, Taylor F, Gray C, O'Brien L, D'Abrew N</AU>
<TI>Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2014-06-12 09:27:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-12 09:27:06 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006726.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<PB>US National Institutes of Health</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1959" NAME="Hamilton 1959" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>The assessment of anxiety states by rating</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1959</YR>
<VL>32</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebert-1996" MODIFIED="2012-07-17 14:43:07 +0100" MODIFIED_BY="[Empty name]" NAME="Hebert 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hebert MA, Potegal M, Moore T, Evenson AR, Meyerhoff JL</AU>
<TI>Diazepam enhances conditioned defeat in hamsters (Mesocricetus auratus)</TI>
<SO>Pharmacology, Biochemistry and Behavior</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>3</NO>
<PG>405-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heinzelmann-2013" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Heinzelmann 2013" TYPE="JOURNAL_ARTICLE">
<AU>Heinzelmann M, Gill J</AU>
<TI>Epigenetic mechanisms shape the biological response to trauma and risk for PTSD: a critical review</TI>
<SO>Nursing Research and Practice</SO>
<YR>2013</YR>
<VL>2013</VL>
<PG>417010</PG>
<MD>Epub 2013 Apr 17</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>6</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2014-07-01 16:12:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ipser-2011" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ipser 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ipser JC, Stein DJ</AU>
<TI>Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>6</NO>
<PG>825-40</PG>
<IDENTIFIERS MODIFIED="2013-02-27 07:48:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-27 07:48:24 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1017/S1461145711001209"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1995" NAME="Kessler 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB</AU>
<TI>Posttraumatic stress disorder in the National Comorbidity Survey</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>12</NO>
<PG>1048-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-2005" NAME="Kessler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE</AU>
<TI>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>2</NO>
<PG>593-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krystal-2009" MODIFIED="2014-07-01 13:10:54 +0100" MODIFIED_BY="[Empty name]" NAME="Krystal 2009" TYPE="JOURNAL_ARTICLE">
<AU>Krystal JH, Neumeister A</AU>
<TI>Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience</TI>
<SO>Brain Research</SO>
<YR>2009</YR>
<VL>1293</VL>
<PG>13-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lumley-2000" MODIFIED="2012-07-17 14:44:49 +0100" MODIFIED_BY="[Empty name]" NAME="Lumley 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lumley LA, Charles RF, Charles RC, Hebert MA, Morton DM, Meyerhoff JL</AU>
<TI>Effects of social defeat and of diazepam on behavior in a resident-intruder test in male DBA/2 mice</TI>
<SO>Pharmacology, Biochemistry and Behavior</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>3</NO>
<PG>433-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundbeck-2003" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2003" TYPE="OTHER">
<AU>Lundbeck Institute</AU>
<TI>Psychotropics</TI>
<SO>http://www.psychotropics.dk/</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Massad-2006" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Massad 2006" TYPE="JOURNAL_ARTICLE">
<AU>Massad PM, Hulsey TL</AU>
<TI>Causal attributions in posttraumatic stress disorder: implications for clinical research and practice</TI>
<SO>Psychotherapy (Chic)</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>2</NO>
<PG>201-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayou-2000" NAME="Mayou 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mayou RA, Ehlers A, Hobbs M</AU>
<TI>Psychological debriefing for road traffic accident victims. Three-year follow-up of a randomised controlled trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>589-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCleery-2004" MODIFIED="2012-07-17 14:36:02 +0100" MODIFIED_BY="[Empty name]" NAME="McCleery 2004" TYPE="JOURNAL_ARTICLE">
<AU>McCleery JM, Harvey AG</AU>
<TI>Integration of psychological and biological approaches to trauma memory: implications for pharmacological prevention of PTSD</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>6</NO>
<PG>485-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meewisse-2007" MODIFIED="2014-07-01 13:12:21 +0100" MODIFIED_BY="[Empty name]" NAME="Meewisse 2007" TYPE="JOURNAL_ARTICLE">
<AU>Meewisse ML, Reitsma JB, de Vries GJ, Gersons BP, Olff M</AU>
<TI>Cortisol and post-traumatic stress disorder in adults: systematic review and meta-analysis</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>191</VL>
<PG>387-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mueser-2008" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Mueser 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mueser KT, Rosenberg SD, Xie H, Jankowski MK, Bolton EE, Lu W, et al</AU>
<TI>A randomized controlled trial of cognitive-behavioral treatment for posttraumatic stress disorder in severe mental illness</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2008</YR>
<VL>76</VL>
<NO>2</NO>
<PG>259-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-2013" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Nicholson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Nicholson EL, Bryant RA, Felmingham KL</AU>
<TI>Interaction of noradrenaline and cortisol predicts negative intrusive memories in posttraumatic stress disorder</TI>
<SO>Neurobiology of Learning and Memory</SO>
<YR>2013</YR>
<VL>112</VL>
<PG>204-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nickerson-2013" MODIFIED="2014-07-01 13:12:55 +0100" MODIFIED_BY="[Empty name]" NAME="Nickerson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Nickerson A, Aderka IM, Bryant RA, Hofmann SG</AU>
<TI>The role of attribution of trauma responsibility in posttraumatic stress disorder following motor vehicle accidents</TI>
<SO>Depression and Anxiety</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>5</NO>
<PG>483-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-2007" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Norris 2007" TYPE="BOOK_SECTION">
<AU>Norris F, Sloane LB</AU>
<TI>The epidemiology of trauma and PTSD</TI>
<SO>Handbook of PTSD: Science and Practice</SO>
<YR>2007</YR>
<PG>78-98</PG>
<ED>Friedman MJ, Keane TM, Resick PA</ED>
<PB>Guilford Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ozer-2003" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ozer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ozer EJ, Best SR, Lipsey TL, Weiss DS</AU>
<TI>Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis</TI>
<SO>Psychological Bulletin</SO>
<YR>2003</YR>
<VL>129</VL>
<NO>1</NO>
<PG>52-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pe_x00f1_alba-2009" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Peñalba 2009" TYPE="COCHRANE_REVIEW">
<AU>Peñalba V, McGuire H, Leite JR</AU>
<TI>Psychosocial interventions for prevention of psychological disorders in law enforcement officers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-02-27 07:17:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-27 07:17:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005601.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pitman-1989" MODIFIED="2014-07-01 13:13:40 +0100" MODIFIED_BY="[Empty name]" NAME="Pitman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Pitman RK</AU>
<TI>Post-traumatic stress disorder, hormones, and memory</TI>
<SO>Biological Psychiatry</SO>
<YR>1989</YR>
<VL>26</VL>
<NO>3</NO>
<PG>221-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pitman-2005" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Pitman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pitman RK, Delahanty DL</AU>
<TI>Conceptually driven pharmacologic approaches to acute trauma</TI>
<SO>CNS Spectrums</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>99-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robert-1999" MODIFIED="2014-04-08 08:02:30 +0100" MODIFIED_BY="[Empty name]" NAME="Robert 1999" TYPE="JOURNAL_ARTICLE">
<AU>Robert R, Blakeney PE, Villarreal C, Rosenberg L, Meyer WJ 3rd</AU>
<TI>Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study</TI>
<SO>Journal of the American Academy of Child &amp; Adolescent Psychiatry</SO>
<YR>1999</YR>
<VL>38</VL>
<NO>7</NO>
<PG>873-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robert-2008" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Robert 2008" TYPE="JOURNAL_ARTICLE">
<AU>Robert R, Tcheung WJ, Rosenberg L, Rosenberg M, Mitchell C, Villarreal C, et al</AU>
<TI>Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study</TI>
<SO>Burns</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>7</NO>
<PG>919-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2010" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 2010" TYPE="COCHRANE_REVIEW">
<AU>Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI</AU>
<TI>Multiple session early psychological interventions for the prevention of post-traumatic stress disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-02-27 06:57:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-27 06:57:52 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006869.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rose-2002" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Rose 2002" TYPE="COCHRANE_REVIEW">
<AU>Rose SC, Bisson J, Churchill R, Wessely S</AU>
<TI>Psychological debriefing for preventing post traumatic stress disorder (PTSD)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-02-27 07:11:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-27 07:11:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000560"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ruzek-2001" MODIFIED="2013-02-06 13:35:13 +0000" MODIFIED_BY="[Empty name]" NAME="Ruzek 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ruzek J, Watson P</AU>
<TI>Early intervention to prevent PTSD and other trauma-related problems</TI>
<SO>PTSD Research Quarterly</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>4</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sapolsky-2000" MODIFIED="2014-04-08 08:03:45 +0100" MODIFIED_BY="[Empty name]" NAME="Sapolsky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sapolsky RM</AU>
<TI>Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>10</NO>
<PG>925-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schelling-1999" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Schelling 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Stoll C, Kapfhammer HP, Rothenhausler HB, Krauseneck T, Durst K, et al</AU>
<TI>The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors</TI>
<SO>Critical Care Medicine</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>12</NO>
<PG>2678-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schnurr-2009" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Schnurr 2009" TYPE="JOURNAL_ARTICLE">
<AU>Schnurr PP, Lunney CA, Bovin MJ, Marx BP</AU>
<TI>Posttraumatic stress disorder and quality of life: extension of findings to veterans of the wars in Iraq and Afghanistan</TI>
<SO>Clinical Psychology Review</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shalev-2006" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Shalev 2006" TYPE="CONFERENCE_PROC">
<AU>Shalev A, Freedman S, Adessky R, Watson P</AU>
<TI>Early interventions for PTSD: what works, and for whom?</TI>
<SO>22nd Annual Meeting, International Society for Traumatic Stress Studies, November 4-7, Hollywood, CA</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheehan-1996" NAME="Sheehan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sheehan DV, Harnett-Sheehan K, Raj BA</AU>
<TI>The measurement of disability</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11 Suppl 3</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solomon-1997" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Solomon 1997" TYPE="JOURNAL_ARTICLE">
<AU>Solomon SD, Davidson JR</AU>
<TI>Trauma: prevalence, impairment, service use, and cost</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58 Suppl 5</VL>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sones-2011" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Sones 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sones HM, Thorp SR, Raskind M</AU>
<TI>Prevention of posttraumatic stress disorder</TI>
<SO>Psychiatric Clinics of North America</SO>
<YR>2011</YR>
<VL>34</VL>
<PG>79&#8211;94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1996" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Spitzer 1996" TYPE="BOOK">
<AU>Spitzer R, Williams J, Gibbons M</AU>
<SO>Instructional Manual for the Structured Clinical Interview for DSM-IV</SO>
<YR>1996</YR>
<PB>New York State Psychiatric Institute</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2014-06-12 09:23:47 +0100" MODIFIED_BY="Jonathan Ipser" NAME="Sterne 2011" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1994" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG</AU>
<TI>Why sources of heterogeneity in meta-analysis should be investigated</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6965</NO>
<PG>1351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turpin-2005" MODIFIED="2013-02-06 13:38:18 +0000" MODIFIED_BY="[Empty name]" NAME="Turpin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Turpin G, Downs M, Mason S</AU>
<TI>Effectiveness of providing self-help information following acute traumatic injury: randomised controlled trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>76-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Emmerik-2008" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Van Emmerik 2008" TYPE="JOURNAL_ARTICLE">
<AU>Van Emmerik AA, Kamphuis JH, Emmelkamp PM</AU>
<TI>Treating acute stress disorder and posttraumatic stress disorder with cognitive behavioral therapy or structured writing therapy: a randomized controlled trial</TI>
<SO>Psychotherapy and Psychosomatics</SO>
<YR>2008</YR>
<VL>77</VL>
<NO>2</NO>
<PG>93-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Zuiden-2013" MODIFIED="2014-04-08 08:05:53 +0100" MODIFIED_BY="[Empty name]" NAME="van Zuiden 2013" TYPE="JOURNAL_ARTICLE">
<AU>van Zuiden M, Kavelaars A, Geuze E, Olff M, Heijnen CJ</AU>
<TI>Predicting PTSD: pre-existing vulnerabilities in glucocorticoid-signaling and implications for preventive interventions</TI>
<SO>Brain, Behavior, and Immunity</SO>
<YR>2013</YR>
<VL>30</VL>
<PG>12-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verbeke-2000" NAME="Verbeke 2000" TYPE="BOOK">
<AU>Verbeke M, Molenberghs G</AU>
<SO>Linear Mixed Models for Longitudinal Data</SO>
<YR>2000</YR>
<PB>Springer</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1992" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ware 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE, Sherbourne CD</AU>
<TI>The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection</TI>
<SO>Medical Care</SO>
<YR>1992</YR>
<VL>30</VL>
<PG>473-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weathers-2001" MODIFIED="2014-07-01 13:17:30 +0100" MODIFIED_BY="[Empty name]" NAME="Weathers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Weathers FW, Keane TM, Davidson JR</AU>
<TI>Clinician-administered PTSD scale: a review of the first ten years of research</TI>
<SO>Depression and Anxiety</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>132-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weisaeth-1989" MODIFIED="2014-07-01 13:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Weisaeth 1989" TYPE="JOURNAL_ARTICLE">
<AU>Weisaeth L</AU>
<TI>Torture of a Norwegian ship's crew. The torture, stress reactions and psychiatric after-effects</TI>
<SO>Acta Psychiatrica Scandinavica. Supplementum</SO>
<YR>1989</YR>
<VL>355</VL>
<PG>63-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1997" MODIFIED="2014-07-01 16:13:04 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1997" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Composite International Diagnostic Interview (CIDI) 2.1</SO>
<YR>1997</YR>
<PB>World Health Organization</PB>
<CY>Geneva, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yehuda-1990" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NAME="Yehuda 1990" TYPE="JOURNAL_ARTICLE">
<AU>Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW</AU>
<TI>Low urinary cortisol excretion in patients with posttraumatic stress disorder</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1990</YR>
<VL>178</VL>
<NO>6</NO>
<PG>366-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yehuda-2006" MODIFIED="2014-04-08 08:08:34 +0100" MODIFIED_BY="[Empty name]" NAME="Yehuda 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yehuda R</AU>
<TI>Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2006</YR>
<VL>1071</VL>
<PG>137-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yehuda-2008" MODIFIED="2014-04-08 08:09:16 +0100" MODIFIED_BY="[Empty name]" NAME="Yehuda 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yehuda R, Bierer LM</AU>
<TI>Transgenerational transmission of cortisol and PTSD risk</TI>
<SO>Progress in Brain Research</SO>
<YR>2008</YR>
<VL>167</VL>
<PG>121-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-07-17 14:28:33 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-07-03 12:56:30 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-07-03 12:56:30 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-07-01 16:03:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delahanty-2012">
<CHAR_METHODS MODIFIED="2014-07-01 16:03:24 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled pilot study</P>
<P>Duration of intervention: 16 days (including 6-day taper off)</P>
<P>Follow-up: 1 and 3 months</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 64 participants were randomised to hydrocortisone and placebo</P>
<P>Mean age: 30.6 (10.7)</P>
<P>Gender: 42 males and 22 females were included in the study</P>
<P>Ethnicity: 14% African-American and 2% Native American</P>
<P>Type of trauma: motor vehicle accidents, falls, assault, and pedestrian and/or car accidents</P>
<P>Diagnostic measure: DSM-IV</P>
<P>Inclusion criteria: participants consisted of 64 injury victims, who met criterion A for exposure to a traumatic event, ranging in age from 18 to 56 who were admitted as trauma inpatients at a Midwestern Level-1 trauma unit. Participants were required to have a minimum score of 27 on the Peritraumatic Dissociative Experiences Questionnaire - Self Report</P>
<P>Exclusion criteria: Quote: "Glasgow Coma Scale (GCS) score of less than 14; exposure to a traumatic event that occurred more than 12 hours before initial medication dose could be given or inability to initiate first medication dose within 12 hours of event; allergy to cortisol or medical/medicinal contraindications to cortisol administration; pregnant or breast-feeding; exposure to a trauma of a potentially ongoing nature (e.g. domestic violence); presence of injuries requiring delayed operative procedures; patient reported corticosteroid use in the previous 6 months; and/or patient had injuries that required treatment with steroids"</P>
<P>Drop-outs: 21 (12/31 in the medication group and 9/33 in the placebo group)</P>
<P>Number of participants with MDD: data not provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention: Quote: "Following consent, the nurse administered the first oral dose [20mg Hydrocortisone (Cortef®, Pharmacia) or placebo capsules] within twelve hours of hospital admission. Participants continued to take either the 20mg hydrocortisone or placebo capsules every twelve hours (bid) for 10 days, followed by a 6-day taper period to avoid any potential adrenal suppression. The medication regimen was tapered by halving the dose every two days"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Clinician-Administered PTSD Scale (CAPS), 36-Item Short-Form Health Survey (SF-36) and the Center for Epidemiological Studies &#8211; Depression Scale (CES-D)</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: yes. Funding for this study was provided by the National Institute of Mental Health (R34 MH73014) and the Ohio Board of Regents</P>
<P>Medication provided by industry: no</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 16:03:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoge-2012">
<CHAR_METHODS MODIFIED="2014-07-01 16:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled pilot study</P>
<P>Duration of intervention: an initial dose was given at the emergency department, followed by a 19-day treatment course at home</P>
<P>Follow-up: 1 and 3 months</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 43 participants were randomised to propranolol and placebo</P>
<P>Mean age: 33.5 (10.2)</P>
<P>Gender: 18 males and 23 females were included in the study</P>
<P>Ethnicity: data not provided</P>
<P>Type of trauma: emergency department</P>
<P>Diagnostic measure: DSM-IV</P>
<P>Inclusion criteria: Quote: "Participant candidates had to experience an event that met the DSM-IV PTSD A.1 (stressor) and A.2 (response) criteria." "The initial eligibility criterion of an ED admission heart rate of 80 BPM or greater was done away with, and the requirement that the traumatic event occur no earlier than 4 h prior to first dose of study medication was extended to from 4 to 12 hours, due to recruitment difficulties"<BR/>
</P>
<P>Exclusion criteria: Quote: "These included physical injury that would complicate participation, hospital stay longer than overnight (the great majority of participants were discharged from the ED the same day), head injury with loss of consciousness, a medical condition that contraindicated the administration of propranolol (e.g., asthma), use of medications with potentially dangerous interactions with propranolol, previous adverse reaction to a &#946;-blocker, blood alcohol concentration above 0.02% or presence of substances of abuse on saliva testing, pregnancy, traumatic event reflecting ongoing victimization, contraindicating psychiatric condition such as psychotic, bipolar, major depressive, or posttraumatic stress disorder from another event, suicidality or homicidality, unwillingness or inability to come to Boston for the research visits, or treating physician did not concur with enrollment in the study"<BR/>
</P>
<P>Drop-outs: 9 of 43 (20.9%). Group-specific drop-out rates were not provided</P>
<P>Number of participants with MDD: 3/20 (15%) on placebo and 3/21 (14.3%) on propranolol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention: Quote: "Following screening, each participant was randomized to receive an initial oral dose of either 40 mg short-acting propranolol or placebo. One hour after this first dose, if systolic blood pressure had not fallen by 10 mmHg or more, or to below 100 mmHg, an additional oral dose of 60 mg long-acting propranolol or placebo was given; all participants received both doses. Participants continued taking long-acting propranolol (or placebo) at home over a 19-day course, starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning only ×3 days, after which the study medication was discontinued"<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Physiological Reactivity, Peritraumatic Emotional Distress Inventory, Clinician Administered PTSD Scale (CAPS)</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: no</P>
<P>Medication provided by industry: no</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mellman-2002">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, placebo-controlled trial</P>
<P>Duration of intervention: 7 days</P>
<P>Follow-up: the final assessment for the trial was 6 weeks after the initial assessment</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 22 participants were randomised to temazepam and placebo</P>
<P>Mean age: 36.1 (11.4)</P>
<P>Gender: 14 men and 8 females</P>
<P>Ethnicity: 18 Hispanic, 2 white and 2 black participants</P>
<P>Type of trauma: motor vehicle accidents, industrial accidents and impersonal assaults</P>
<P>Diagnostic measure: DSM-IV</P>
<P>Inclusion criteria: participants were recruited from a much larger pool of injured patients on the basis of having recall of the incident and endorsing at least moderate impairment of sleep initiation or maintenance and meeting full criteria for at least 2 PTSD symptoms clusters (DSM-IV) during a structured interview assessment, and the ability and willingness to provide written informed consent</P>
<P>Exclusion criteria: intoxication at the time of the incident, brain injury and pre-existing active psychiatric disorders</P>
<P>Drop-outs: 0</P>
<P>Number of participants with MDD: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention:<B> </B>Quote: "Subjects were randomly assigned to placebo taken at bedtime for seven nights or 30mg of temazepam at bedtime for five nights followed by 15mg for two nights"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: CAPS and sleep diary measure</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: yes. Supported by grant MH54006 from the National Institute of Mental Health, Bethesda</P>
<P>Medication provided by industry: no</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 16:05:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pitman-2002">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, pilot study</P>
<P>Duration of intervention: 19 days (including a 9-day taper-off period)</P>
<P>Follow-up: 1 and 3 months</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 41 participants were randomised to propranolol and placebo</P>
<P>Mean age: 34.3 (11)</P>
<P>Gender: 20 males and 21 females</P>
<P>Ethnicity: not specified</P>
<P>Type of trauma: motor vehicle accidents</P>
<P>Diagnostic measure: DSM-IV</P>
<P>Inclusion criteria: patients were included if: Quote: "(a) had just experienced a traumatic event that met the DSM-IV PTSD A.1 (stressor) and A.2 (response) criteria; (b) had a heart rate (HR) of 80 beats per minute (BPM) or greater at the time of ED presentation; (c) were without serious physical injury, systolic blood pressure under 100 mm Hg, substance intoxication, pregnancy or lifetime history of congestive heart failure, heart block or bronchial asthma; (d) upon mental status examination were found competent to understand the purpose of the study and the nature of the procedures; and (e) gave written informed consent after the procedures had been fully explained"<BR/>
</P>
<P>Exclusion criteria: serious physical injury, systolic blood pressure over 100 mm Hg, substance intoxication, pregnancy or lifetime history of congestive heart failure, heart block or bronchial asthma</P>
<P>Drop-outs: 7/18 on propranolol and 8/23 on placebo at the 3-month assessment<B> </B>
</P>
<P>Number of participants with MDD: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention: patients were randomised to begin, within 6 hours of the event, a 10-day course of double-blind propanolol versus placebo 40 mg 4 times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Clinician-Administered PTSD Scale (CAPS)</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 16:05:11 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: yes. Supported by US Public Health Service Grant #MH58671</P>
<P>Medication provided by industry: no</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schelling-2001">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: prospective, randomised, double-blind study</P>
<P>Duration of intervention: hydrocortisone was administered for a median of 18 days (range: 14 to 35 days)</P>
<P>Follow-up: median assessment for PTSD at 31 months (range: 21 to 49 months)</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 20 participants were randomised to propranolol and placebo</P>
<P>Mean range: 52 (23 to 76)</P>
<P>Gender: 8 males and 12 females</P>
<P>Ethnicity: not specified</P>
<P>Type of trauma: septic shock</P>
<P>Diagnostic measure: SCID-IV</P>
<P>Inclusion criteria: Quote: "Patients who had fulfilled the criteria for hyperdynamic septic shock as proposed by the American college of chest physicians/society of critical care medicine"</P>
<P>Exclusion criteria: psychiatric diseases (including alcohol and drug abuse) and those who could not complete a questionnaire in German language</P>
<P>Drop-outs: 50% (20/40) of the randomised sample (11/20 in the hydrocortisone and 9/20 in the placebo group)</P>
<P>Number of participants with MDD:<B> </B>0 (participants were excluded for "pre-existing psychiatry disease")</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention:<B> </B>Quote: "Patients were prospectively and randomly assigned to receive either placebo or hydrocortisone with a loading dose of 100mg given intravenously over 30 minutes, followed by a continuous infusion of 1.8mg/kg/hour. This dose was kept constant for six days. When septic shock was reversed the dose of hydrocortisone was reduced to .08mg for an additional six days and then tapered in steps of 24mg per day."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Structured Clinical Interview for DSM-IV (SCID-IV), Post-Traumatic Stress Syndrome 10-Questions Inventory (PTSS-10Q-I) (German version) and the traumatic memory questionnaire</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: yes. Supported by grants from Hoffman-La Roche, Grenzach-Wyhlen and the Eli-Lilly International Foundation, Bad Homburg, in Germany</P>
<P>Medication provided by industry: unclear</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 16:06:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shalev-2012">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: prospective, randomised, double-blind study. Assignment to 1 of 4 treatment arms (prolonged exposure, cognitive therapy, escitalopram or placebo, and waiting list)</P>
<P>Duration of intervention: escitalopram or placebo was administered for 12 weeks</P>
<P>Follow-up: follow-up assessments were conducted at 5 months and 9 months after trauma exposure. Quote: "The first clinical assessment took place a mean (SD) 19.8 (5.2) days after the traumatic event"</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 46 participants were randomised to propranolol or placebo</P>
<P>Mean range: 38.1 (12.1)</P>
<P>Gender: 23 males and 23 females</P>
<P>Ethnicity: not specified</P>
<P>Type of trauma: motor vehicle accident, terrorist attack and other</P>
<P>Diagnostic measure: CAPS</P>
<P>Inclusion criteria: Quote: "All survivors of qualifying events who met all criteria for PTSD, including the DSM-IV A2 criterion (exposure to a traumatic event that was responded to with fear, helplessness, or horror), but not the 1 month duration criterion Individuals who did not meet criterion A, but only B, C, and D for PTSD were classified as having partial PTSD, and included as part of a separate analysis"</P>
<P>Exclusion criteria: Quote: "Current or past psychosis or bipolar disorder, a current substance abuse problem, other conditions requiring urgent attention (e.g., suicidal ideations or acute grief), or chronic PTSD or if they started treatment elsewhere"</P>
<P>Drop-outs: 6/23 (26.1%) on escitalopram and 13/23 (56.5%) on placebo completed the 8 sessions of treatment, with 1 additional participant on placebo not providing data for the 5-month post-trauma assessment</P>
<P>Number of participants with MDD: 18 (78.3%) and 12 (52.2%) in the escitalopram and placebo arms, respectively</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention:<B> </B>Quote: "An initial dose of 1 tablet (10 mg) daily was increased to 2 tablets after 2 weeks of treatment. Trained psychiatrists provided 4 weekly sessions (weeks 1-4) followed by 4 biweekly sessions (weeks 6-12). At the end of our study, 8 participants with PTSD who received placebo were invited to receive PE"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Clinician-Administered PTSD Scale (CAPS)</P>
<P>Secondary outcomes: PTSD Symptom Scale &#8211; Self-Report Version (PSS-SR), Clinician-Administered PTSD Scale (CAPS, structured interview) and Beck Depression Inventory (BDI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 16:06:09 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: yes. Funding was provided by Lundbeck Pharmaceuticals Ltd. (Denmark)</P>
<P>Medication provided by industry: unclear</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 16:06:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-2007">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: proof-of-concept-study; double-blind, randomised, placebo-controlled trial</P>
<P>Duration of intervention: 14 days (including the up-titration, treatment and taper phases)</P>
<P>Follow-up: 1, 4 and 8 months</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 16:06:50 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 48 participants were randomised to propranolol, gabapentin and placebo</P>
<P>Mean age: 29.4 (10.10)</P>
<P>Gender: 26 males and 22 females</P>
<P>Ethnicity: Quote: "The sample was ethnically diverse: 40% Hispanic, 35% White non-Hispanic, 10% African American, 10% Asian, and 4% Native American"</P>
<P>Type of trauma: Quote: "The most common type of injury was a motor vehicle collision followed by falls, burns, pedestrian versus automobile, assault, and other (e.g. surfing)"</P>
<P>Diagnostic measure: specified structured or semi structured measurement</P>
<P>Inclusion criteria: Quote: "Potential participants were men and women ages 18-65 who were admitted to the University of California San Diego (UCSD) Level 1 Surgical Trauma Centre during the 39-month period from October 2001 through December 2004. Admission to this service reflected a severe physical injury requiring specialized, emergent trauma care"</P>
<P>Exclusion criteria: Quote: "The most common reasons for exclusion were (a) living outside the region such that home monitoring could not be arranged, (b) too medically unstable to participate, (c) did not speak English, or (d) too old or too young"</P>
<P>Drop-outs: 5/17 for propranolol, 4/14 for gabapentin and 1/17 on placebo, as inferred from number of people assessed for PTSD at the 4-month follow-up assessment</P>
<P>Number of participants with MDD: data not provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention:<B> </B>14 days of propranolol, gabapentin or placebo, administered within 48 hours of injury to patients admitted to a surgical trauma centre. Propranolol was started at 20 mg for 3 times daily and up-titrated over 2 days to 40 mg. Gabapentin was started at 300 mg and up-titrated over 2 days to 400 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: the Acute Stress Disorder Scale (ASDS), the Comprehensive International Diagnostic Interview (CIDI), the Center for Epidemiologic Studies Depression Scale (CES-D) and the Posttraumatic Stress Disorder Checklist&#8211;Civilian Version (PCL-C)</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: yes. Supported by NIMH grants MH62037 (R21) and MH64122 (K24) to MBS</P>
<P>Medication provided by industry: no</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weis-2006">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: prospective, randomised, double-blind trial</P>
<P>Duration of intervention: 4 days</P>
<P>Follow-up: 6 months</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 36 participants were randomised to hydrocortisone and placebo</P>
<P>Mean age: 68.5 (range 63 to 73)</P>
<P>Gender: 8 males and 28 females</P>
<P>Ethnicity: not specified</P>
<P>Type of trauma: cardiac surgery</P>
<P>Diagnostic measure: specified structured or semi structured measurement</P>
<P>Inclusion criteria: Quote: "The study was performed in high-risk patients undergoing CS with CPB. High risk was defined as a preoperative left ventricular ejection fraction of less than 35% or an expected duration of CPB of greater than 97 minute"</P>
<P>Exclusion criteria: Quote: "Patients were excluded from the study if they met the following criteria before surgical intervention: pregnancy, emergency operation, hepatic dysfunction (bilirubin 3 mg/dL), renal dysfunction (plasma creatinine 2 mg/dL), a positive serologic test result for HIV, manifest insulin-dependent diabetes mellitus, an extracardial septic focus, chronic or acute inflammatory disease, and inability to provide informed consent. In addition, patients who required glucocorticoids other than hydrocortisone were excluded"</P>
<P>Drop-outs: 5/19 in the medication group and 3/17 in the placebo group. 2 of these participants were not technically drop-outs, but were not included in the analysis due to missing data</P>
<P>Number of participants with MDD: not assessed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention:<B> </B>Quote:<B> </B>"Hydrocortisone administration started with a loading dose (100 mg over 10 minutes administered intravenously) before induction of anesthesia, followed by a continuous infusion of 10mg/h for 24 hours (postoperative day [POD] 1), which was reduced to 5mg/h on POD 2 and then tapered to 3 X 20 mg administered intravenously on POD 3 and 3 X 10 mg administered intravenously on POD 4"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: the Short Form (36) Health Survey (SF-36) and Posttraumatic Symptom Scale (PTSS-10). Evaluation of traumatic memories: all patients were asked to complete a structured and validated questionnaire, evaluating different categories of traumatic memory from ICU therapy</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: unclear</P>
<P>Medication provided by industry: unclear</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zohar-2011a">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised, double-blind, placebo-controlled pilot study</P>
<P>Duration of intervention: single dose 1.5 to 5 hours after the traumatic event</P>
<P>Follow-up: 2 weeks, 1 month and 3 months after the trauma</P>
<P>Placebo run-in: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size: 25 participants were randomised to hydrocortisone and placebo</P>
<P>Mean age: 35.16 (14)</P>
<P>Gender: 14 males and 11 females</P>
<P>Ethnicity: not specified</P>
<P>Type of trauma: traffic accidents, work accidents and snake bites</P>
<P>Diagnostic measure: specified structured or semi structured measurement</P>
<P>Inclusion criteria: Quote: "Seventy consecutive patients who were exposed to a traumatic event, experienced either acute stress reaction or sub-threshold acute stress reaction, and met the DSM-IV PTSD A.1 (stressor) and A.2 (response) criteria (fulfilling criteria A, 2 of the symptoms in criteria B, 3 out of 4 of criteria C, D, E, and F, and meeting criterion H of the ASD criteria set out in DSM-IV) were recruited from the emergency department at the Chaim Sheba Medical Center"<BR/>
</P>
<P>Exclusion criteria: Quote: "Exclusion criteria included serious physical injury (a score of 3 or above on the Abbreviated Injury Scale), brain trauma, substance abuse disorders, cardiac pacemaker implant, a history of epilepsy, neurosurgery, chronic medical conditions of any sort. Medication specific exclusion criteria included hypersensitivity to hydrocortisone, pregnancy, or treatment for asthma"</P>
<P>Drop-outs: 6/15 (40%) on hydrocortisone and 2/10 (20%) on placebo</P>
<P>Number of participants with MDD: MDD was not assessed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention:<B> </B>Quote:<B> </B>"Hydrocortisone or placebo was given between 1.5 and 5.5 hours following the traumatic event. Patients received hydrocortisone intravenously in a single bolus at a dose ranging from 100 to 140mg based on body weight: 100 mg for weights of 60&#8211;69kg, 120 mg for weights of 70&#8211;89kg, and 140mg for weights of 90&#8211;99kg"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Clinician-Administered PTSD Scale (CAPS), visual analogue scales for anxiety (VAS-A) and depression (VAS-D)</P>
<P>Secondary outcomes: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Industry-funded: no</P>
<P>Medication provided by industry: no</P>
<P>Any of the authors work for industry: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BPM: beats per minute</P>
<P>CAPS: Clinician-Administered PTSD Scale</P>
<P>CPB: cardiopulmonary bypass</P>
<P>CS: cardiac surgery</P>
<P>DSM-IV: Diagnostic and Statistical Manual IV</P>
<P>ED: emergency department</P>
<P>GEE: generalised estimating equation</P>
<P>ICU: intensive care unit</P>
<P>MDD: major depressive disorder</P>
<P>NIMH: National Institute of Mental Health</P>
<P>PTSD: post-traumatic stress disorder</P>
<P>SCID-IV: Structured Clinical Interview for DSM-IV</P>
<P>SD: standard deviation</P>
<P>SSRI: selective serotonin reuptake inhibitor</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse prevention study; participants were already diagnosed with PTSD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gelpin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial and no placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martenyi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse prevention study; participants were already diagnosed with PTSD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martenyi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse prevention study; participants were already diagnosed with PTSD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schelling-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>No comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaiva-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were not randomised to treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PTSD: post-traumatic stress disorder</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azad-2007">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, interventional, randomised, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>92 high-risk patients after cardiac surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Hydrocortisone in stress doses versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: immunologic markers, health care-related quality of life, PTSD<BR/>Secondary outcomes: early clinical outcome parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes were assessed at 1.5 years. Secondary outcomes were assessed at 1 year</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marx-2006">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel-group, double-blind, controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>12 veterans, 18 to 55 years of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Paroxetine 10 mg to 40 mg (flexible dosing) versus placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: improvement in PTSD symptoms as determined by the Clinician Administered PTSD Scale (CAPS)</P>
<P>Secondary outcomes: short PTSD Rating Interview, Connor Davidson Resilience Scale, Hospital Anxiety and Depression Scale, Clinical Global Impressions of Severity and of Improvement Scales, Symptom Checklist 90 and the Sheehan Disability Scale (SDS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome assessed at baseline and at 12 weeks. All secondary outcomes assessed at 12 weeks of intervention</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simon-2005">
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, flexible-dose, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>60 study participants meeting criteria for the A1, A2 and at least 1 additional ASD criterion (i.e., B, C and or D criteria), as determined by the Acute Stress Disorder Interview upon initial evaluation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Escitalopram (10 to 40 mg/day) versus placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: symptoms of post-traumatic stress disorder, symptoms of acute stress disorder</P>
<P>Secondary outcome: Clinical Global Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>ASD: acute stress disorder<BR/>PTSD: post-traumatic stress disorder</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-07-01 16:09:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zohar-2009">
<CHAR_STUDY_NAME MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>PTSD prevention using escitalopram</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Intervention model: parallel assignment<BR/>Masking: double-blind (subject, investigator)<BR/>Primary purpose: prevention</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Ages eligible for study:18 years to 65 years</P>
<P>Genders eligible for study: both</P>
<P>Accepts healthy volunteers: no</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention: 10 to 20 mg/day of escitalopram versus 1/2 capsules of placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: CAPS</P>
<P>Secondary outcomes: no information provided</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>June 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-12-11 12:57:56 +0000" MODIFIED_BY="[Empty name]">
<P>Contact: Joseph Zohar, MD: <A HREF="mailto:jzohar%40post.tau.ac.il?subject=NCT01039766, SHEBA-09-7128-AJW-CTIL, The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)">jzohar@post.tau.ac.il</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of primary outcome at 1-year follow-up</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zohar-2010">
<CHAR_STUDY_NAME MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>The efficacy of a single dose of intranasal oxytocin in the prevention of post traumatic stress disorder (PTSD)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study type: interventional</P>
<P>Allocation: randomised</P>
<P>Endpoint classification: efficacy study</P>
<P>Intervention model: parallel assignment</P>
<P>Masking: double-blind (subject, caregiver, investigator, outcomes assessor)</P>
<P>Primary purpose: prevention</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Ages eligible for study: 18 67 years</P>
<P>Genders eligible for study: both</P>
<P>Inclusion criteria: (1) Persons over the age of 18, who have been exposed to an event meeting the DSM-IV "A.1" criterion for trauma exposure, expressing marked anxiety, and/or emotional distress and/or dissociation, as assessed by the visual analogue scales; (2) the traumatic event occurred up to 6 hours prior to the arrival to the emergency room; (3) the person can and is willing to provide written, informed consent to participate in the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention: oxytocin and placebo - saline nasal spray</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: the primary outcome measure is DSM-IV diagnosis of PTSD at the end of the trial</P>
<P>Secondary outcome: the secondary outcome measure is the severity of PTSD as expressed by the Clinician Administered PTSD Scale (CAPS), at the end of the trial<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>February 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-06-19 10:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>Contact: Joseph Zohar, MD: <A HREF="mailto:jzohar%40post.tau.ac.il?subject=NCT01039766, SHEBA-09-7128-AJW-CTIL, The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)">jzohar@post.tau.ac.il</A>
</P>
<P>Contact: Shlomit Cwikel-Hamzany, MD: <A HREF="mailto:shlomitch%40gmail.com?subject=NCT01039766, SHEBA-09-7128-AJW-CTIL, The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)">shlomitch@gmail.com</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zohar-2011b">
<CHAR_STUDY_NAME MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized placebo-controlled trial of hydrocortisone in PTSD prophylaxis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study type: interventional</P>
<P>Allocation: randomised</P>
<P>Endpoint classification: efficacy study</P>
<P>Intervention model: parallel assignment</P>
<P>Masking: double-blind (subject, caregiver, investigator, outcomes assessor)</P>
<P>Primary purpose: prevention</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Ages eligible for study: no information provided</P>
<P>Genders eligible for study: no information provided</P>
<P>Inclusion criteria: no information provided</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention: single injection of 90 to 140 mg (proportioned to body weight) of hydrocortisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures: no information provided</P>
<P>Secondary outcome measures: no information provided</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>August 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Contact: Joseph Zohar, MD; <A HREF="mailto:jzohar%40post.tau.ac.il?subject=NCT01039766, SHEBA-09-7128-AJW-CTIL, The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)">jzohar@post.tau.ac.il</A>
</P>
<P>Program Officer: Farris K. Tuma; ftuma@mail.nih.gov</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>CAPS: Clinician-Administered PTSD Scale<BR/>DSM-IV: Diagnostic and Statistical Manual IV<BR/>PTSD: post-traumatic stress disorder<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-01 16:16:34 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-07-01 16:16:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>Participants were randomised to either hydrocortisone or placebo. The investigators indicated in response to a request for additional information that "a random number table was used to generate the randomization sequence" (11 December 2013)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>Information about generation of the randomisation sequence was not provided. Quote: "Following screening, each participant was randomized to receive an initial oral dose of either 40 mg short-acting propranolol or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>Predetermined randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>Participants were randomly assigned to treatment and comparison. However, the procedure was not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>Quote: "In this study, patients were prospectively randomised to receive either stress doses of hydrocortisone or placebo (saline). Patients were assigned to random permuted blocks (G. Schelling; personal correspondence: 15/09/2011)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 16:16:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>An equipoise-stratified randomisation procedure was employed, though no information is provided on how this randomisation sequence was generated. Quote: "The equipoise-stratified randomization is a method for randomly allocating participants to interventions in treatment studies that include more than 2 arms ... It allows potential participants to decline treatment options that they do not desire and to be randomly assigned to the remaining arms. By making that choice, each participant assigns himself or herself to a "stratum" which consists of all the options that he or she finds equally acceptable"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>Participants were randomised to receive propranolol, gabapentin or placebo. Quote: "A randomised schedule was set up and maintained by the UCSB Research Pharmacy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "The patients were randomly assigned to one of two treatment groups with the use of a computer-generated randomisation list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>Quote: "The participants were randomised by a predetermined program, and entered in a double blind, placebo-controlled design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>The investigators indicated in response to a request for additional information that "the group into which a participant was allocated was concealed from the study investigators via identical pills/blister packs. They were prepared by the hospital's pharmacist who was a co-author - he maintained the blind so that, in case of adverse reaction, the blind could be broken quickly - he had no contact with any of the participants" (11 December 2013)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>Lead author confirmed that "the research pharmacy makes up the active drug and placebo to look the same" (E. Hoge; personal correspondence: 26 November 2013)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>Medication schedule was known only to the research pharmacist (TA Mellman; personal correspondence: 09 September 2011)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>The study did not report on how the intervention was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>Quote:"Fifty-milliliter syringes containing 100 mg of hydrocortisone-21-hemisuccinate (Upjohn, Heppenheim, Germany) diluted in physiologic saline solution or placebo were prepared daily and labelled study medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>Quote: "Concealed tablets of either 10 mg of escitalopram or placebo were prepared and coded by Lundbeck Pharmaceuticals (Copenhagen, Denmark) and were supplied to clinicians by a research associate"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>Quote: "When a subject was enrolled, the study nurse notified one of the attending physicians on the Trauma Service, who authorized the Research Pharmacy to provide the medication supplies (according to the randomization schedule) to the subject"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Quote: "The vials were prepared by a study nurse who was not involved in the care of patients participating in the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>Quote from Dr. Hagit (11 December 2013): "Hydrocortisone or placebo was given intravenously and has been prepared by another physician. IV bags were numbered and were the same for both treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>Blinding procedures were not specified, but the study was described as double-blinded. Quote: "Following eligibility determination, participants were consented in-hospital and randomly assigned, in double-blind fashion, to either a 10-day course (plus a 6-day taper period) of hydrocortisone or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>No description of blinding is provided in the study report, though the protocol for this study (NCT00158262) describes this study as "Double Blind (Subject, Investigator)". Lead author confirmed that "subjects, the psychologist who did the SCID, and the study nurses who had contact with patients, were all blinded to treatment allocation through the use of blinded medication" (E. Hoge; personal correspondence: 26 November 2013)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>Medication was placed in identical capsules (TA Mellman; personal correspondence: 09 September 2011)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>The study was described as "double-blind", though no information was provided on which parties were blinded and how blinding was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>Quote: "The patients were blinded regarding the facts that their interviewers were psychiatrists and that the aim of the interviews was the diagnosis of PTSD. They were told that their interviewers were doctors with special training in interviewing techniques and that the object of the interviews was their memories from intensive care treatment and their current emotional well-being"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>Both participants and those administering the medication were blinded. Quote: "Trained psychiatrists provided 4 weekly sessions (weeks 1-4) followed by 4 biweekly sessions (weeks 6-12). The concealment was broken and added to the study's data file at the end of the study". Quote: "To separate the pharmacological effect of an SSRI from that of receiving medication and psychiatric care, this blinded group [SSRIs versus placebo comparison] includes both the active agent and placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>All study medications were supplied in identical capsules. Quote: "All study medications were supplied in identical capsules to avoid breaking the blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>The study was described as "double-blind", though no information was provided on which parties were blinded and how blinding was achieved. Quote: "One group of patients received stress doses of hydrocortisone (Pharmacia &amp; Upjohn, Erlangen, Germany; the hydrocortisone group) and patients from the other group (the placebo group) received normal saline in identical vials in a double-blind fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>Although described as double-blinded, the procedure employed was not specified. Quote: "The participants were randomised by a predetermined program, and entered in a double blind, placebo-controlled design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>The investigators indicated in response to a request for additional information that "individuals who assessed the study outcomes were blinded to the group to which participants had been assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>No description of outcome assessment blinding is provided in the study report. Lead author confirmed that "subjects, the psychologist who did the SCID, and the study nurses who had contact with patients, were all blinded to treatment allocation through the use of blinded medication" (E. Hoge; personal correspondence: 26 November 2013)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>No information was provided on the blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>The study was described as "double-blind", though no information was provided on which parties were blinded and how blinding was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>Quote: "For the interviews, the psychiatrists were blinded with regard to treatment characteristics (group assignment, principal diagnoses, traumatic duration of treatment, etc.). They were informed only that the patients were long-term survivors of care"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>5-month (CA-2) and 9-month (CA-3) assessments were blinded. Quote: "Because those who conducted the CA-2 and CA-3 were blinded to treatment attendance and adherence, the resulting comparisons include completers, partial completers, and noncompleters and thereby represent the total yield of participants randomly assigned to an intervention"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>Quote: "The study nurse, who was blinded to treatment allocation, conducted assessments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>The study was described as "double-blind", though no information was provided on which parties were blinded and how blinding was achieved. Quote: "One group of patients received stress doses of hydrocortisone (Pharmacia &amp; Upjohn, Erlangen, Germany; the hydrocortisone group) and patients from the other group (the placebo group) received normal saline in identical vials in a double-blind fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>Assessment was blinded. Quote: "Ratings of ASD and PTSD symptoms, anxiety, and depression were carried out at 4 time points &#8212; before the intervention, at 2 weeks, 1 month and 3 months after the trauma &#8212; by an expert investigator who was blind to the treatment condition"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-06-06 14:31:20 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>The most common reason for loss to follow-up in both the hydrocortisone and placebo group was inability to contact the participants at follow-up (11/12 drops on hydrocortisone and 9/9 on placebo). Quote: "There were no differences between drop-outs and participants who were retained through the protocol on any study variable. There was no differential drop out between the hydrocortisone and placebo groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>Proportion and characteristics of participants who dropped out by group is not described. Nevertheless, the total proportion of drop-outs (20.9%) is relatively low, suggesting that drop-out rates may not have biased the outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>There were no drop-outs reported during this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>Equivalent numbers of drop-outs were reported at the 3-month assessment for the propranolol and placebo groups. No information was provided on the reasons for study withdrawal, and whether they differed by group, however</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>Exclusions were conducted after randomisation for this study, making it difficult to determine whether participants who did not survive to follow-up (5 on hydrocortisone and 6 on placebo) would have been excluded. The exclusion/drop-out rates were similar between the groups (11/20 and 9/20 in the hydrocortisone and placebo groups, respectively), though no information was provided regarding differences between those who were assessed and those who were not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>A greater proportion of participants dropped out from the placebo (14/23; 60.9%) than the escitalopram (6/23; 26%) arms at the 5-month assessment. These participants were not contacted to obtain information on their reasons for withdrawing from treatment" (AY Shalev; personal correspondence: 5 December 2013)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>A higher proportion of drop-outs was observed in the medication groups (propanolol: 29.4% and gabapentin: 28.6%) versus placebo (5.9%). Investigators employed a GEE modelling approach to try and accommodate missing data. No data on reasons for study withdrawal were provided, though. Quote: "And finally, although our rate of follow-up (&#8776;80% at 4 months) was satisfactory, the possibility of differential drop-out across groups creates a missing data problem that even the use of GEE analyses may not solve"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Similar proportions of patients withdrew from the hydrocortisone (5/19; 26.3%) and placebo (3/17; 17.6%) groups. Between-group comparisons on patient and treatment characteristics for the fully randomised sample as well as the sample excluding drop-outs were virtually identical, suggesting that outcomes for the drop-outs would have been similar to those retained in the study. Quote: "There were no significant differences with regard to patient or treatment characteristics between included or excluded patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>A larger proportion of participants were excluded from the hydrocortisone (6/15; 40%) than the placebo groups (2/10; 20%). No information was provided regarding the reasons for treatment withdrawal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>The study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>The outcomes are not described in the study protocol available on ClinicalTrials.gov (NCT00158262)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>The study protocol was not available for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>The study protocol was not available for this trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>The study protocol was not available for this trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>The protocol for this study was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>The study protocol was not available for this trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>The study protocol was not available for this trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>The study protocol was not available for this trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Delahanty-2012">
<DESCRIPTION>
<P>No other source of bias was identified for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoge-2012">
<DESCRIPTION>
<P>No other source of bias was identified for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mellman-2002">
<DESCRIPTION>
<P>Study was terminated at 6 weeks after initial assessment, or in 50% of cases when non-study medications were indicated. Quote: "The final assessment for the trial was 6 weeks after the initial assessment or, in one half of cases, just prior to initiating nonstudy medication, which was initiated on the basis of the clinical judgment of the investigators when insomnia and/or other PTSD-related symptoms that were distressing to the subject did not diminish during or shortly after the trial (intent-to-treat analysis)"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pitman-2002">
<DESCRIPTION>
<P>No other source of bias was identified for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schelling-2001">
<DESCRIPTION>
<P>Funding for study provided by pharmaceutical companies. Additionally, participants receiving placebo required higher norepinephrine doses than participants on hydrocortisone (though this difference was not statistically significant). The authors concede that this may be an alternative explanation of higher PTSD onset in the placebo group, as previous studies have documented higher urinary excretion of norepinephrine in PTSD patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shalev-2012">
<DESCRIPTION>
<P>Funding for study provided by industry. Additionally, in the equipoise-stratified randomisation scheme employed, participants could indicate 2 of the 4 treatment arms they did not want to be assigned to. A large proportion of eligible participants (42.6%) refused treatment with escitalopram or placebo. Since industry funding and self exclusion from the medication arms would be expected to bias the study finding towards an effect for medication, we have interpreted the absence of such an effect as an indication that bias did not occur</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stein-2007">
<DESCRIPTION>
<P>No other source of bias was identified for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weis-2006">
<DESCRIPTION>
<P>Participants receiving hydrocortisone required significantly lower norepinephrine doses (to "counteract vasodilatory hypotension") than participants on placebo. As noted for the similar finding in Schelling 2001, this might provide an alternative explanation of higher PTSD onset in the placebo group, as previous studies have documented higher urinary excretion of norepinephrine in PTSD patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-01 14:03:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zohar-2011a">
<DESCRIPTION>
<P>No other source of bias was identified for this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-07-03 12:48:12 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-07-03 12:47:57 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-12-11 10:56:56 +0000" MODIFIED_BY="Grade Profiler">Propranolol compared to placebo for preventing post-traumatic stress disorder (PTSD)</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Propranolol compared to placebo for preventing post-traumatic stress disorder (PTSD)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> adult<B> </B>participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for PTSD at study recruitment</P>
<P>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> propranolol<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Propranolol</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Treatment efficacy</B>
<BR/>CAPS, CIDI<BR/>Follow-up: median 3 months</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.62 </B>
<BR/>(0.24 to 1.59)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>118<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
<BR/>(24 to 159)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
<BR/>(48 to 318)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CAPS</B>: Clinician-Administered PTSD Scale; <B>CI</B>: confidence interval; <B>CIDI</B>: Comprehensive International Diagnostic Interview; <B>RR</B>: risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The assumed risk in the control group is based on an estimated event rate of 10% and 20%, as per <LINK REF="REF-Norris-2007" TYPE="REFERENCE">Norris 2007</LINK>.</P>
<P>
<SUP>2</SUP>Approximately five times as many drop-outs prior to the follow-up assessment were observed in the propranolol than in the placebo groups in one study (29.4% versus 5.9% of the respective samples). Another study provided little information on how allocation was concealed and whether/how blinding of the outcome was performed.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-07-03 12:48:12 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-12-11 13:10:01 +0000" MODIFIED_BY="Grade Profiler">Hydrocortisone compared to placebo for preventing post-traumatic stress disorder (PTSD)</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Hydrocortisone compared to placebo for preventing post-traumatic stress disorder (PTSD)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> adult<B> </B>participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for PTSD at study recruitment<BR/>
<B>Settings: </B>in- and outpatients<BR/>
<B>Intervention:</B> hydrocortisone<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Hydrocortisone</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Treatment efficacy</B>
<BR/>CAPS, SCID-IV, PTSS-10Q-I<BR/>Follow-up: median 4.5 months</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.17 </B>
<BR/>(0.05 to 0.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>165<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>123</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(5 to 56)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
<BR/>(10 to 112)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CAPS</B>: Clinician-Administered PTSD Scale; <B>CI</B>: confidence interval;<B> PTSS-10Q-I</B>: Post-Traumatic Stress Syndrome 10-Questions Inventory; <B>RR</B>: risk ratio; <B>SCID-IV</B>: Structured Clinical Interview for DSM-IV</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The assumed risk in the control group is based on an estimated event rate of 10% and 20%, as per<SUP> </SUP>
<LINK REF="REF-Norris-2007" TYPE="REFERENCE">Norris 2007</LINK>.</P>
<P>
<SUP>2</SUP>Half of the trials reported administering higher levels of norepinephrine to patients on placebo than medication, which may have confounded the evidence of a treatment effect. In a third trial, the differential proportion of drop-outs between interventions suggests possible attrition bias.</P>
<P>
<SUP>3</SUP>Few participants and few events and thus wide confidence intervals.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-07-03 12:30:21 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-07-03 12:30:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Propranolol versus placebo</NAME>
<DICH_OUTCOME CHI2="0.1824182914452487" CI_END="1.5926330988914672" CI_START="0.244901701752912" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6245306687317558" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.2021157372074843" LOG_CI_START="-0.6110081970748307" LOG_EFFECT_SIZE="-0.20444622993367323" METHOD="IV" MODIFIED="2014-07-01 13:56:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9128268258745448" P_Q="1.0" P_Z="0.3243297254591444" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="61" WEIGHT="100.00000000000001" Z="0.9855994407511057">
<NAME>Treatment efficacy</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours propranolol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3370820139347104" CI_START="0.0974673780552704" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3686739531172212" LOG_CI_START="-1.0111407166217574" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2013-11-28 20:06:25 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.8105099671974472" STUDY_ID="STD-Hoge-2012" TOTAL_1="22" TOTAL_2="21" VAR="0.6569264069264069" WEIGHT="34.72737634454809"/>
<DICH_DATA CI_END="6.500220038038757" CI_START="0.06279464540539377" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8129280581334104" LOG_CI_START="-1.2020773876327993" LOG_EFFECT_SIZE="-0.19457466474969443" MODIFIED="2012-07-10 09:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="1.1836241732808939" STUDY_ID="STD-Pitman-2002" TOTAL_1="18" TOTAL_2="23" VAR="1.4009661835748792" WEIGHT="16.28399802327259"/>
<DICH_DATA CI_END="2.857139834489761" CI_START="0.19687520827991023" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4559314961969352" LOG_CI_START="-0.7058089694135351" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2012-07-10 09:50:52 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.6824121002076413" STUDY_ID="STD-Stein-2007" TOTAL_1="17" TOTAL_2="17" VAR="0.4656862745098038" WEIGHT="48.988625632179335"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5097419406590475" CI_END="1.837830963335841" CI_START="0.2927243060284018" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7334696949022457" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.26430556414125495" LOG_CI_START="-0.5335412149227228" LOG_EFFECT_SIZE="-0.1346178253907339" METHOD="MH" MODIFIED="2014-04-01 10:48:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7750165027275357" P_Q="1.0" P_Z="0.5083587879319009" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="52" WEIGHT="100.0" Z="0.6613953865991173">
<NAME>Sensitivity analysis - observed cases</NAME>
<GROUP_LABEL_1>Propranolol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours propanolol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3370820139347104" CI_START="0.0974673780552704" EFFECT_SIZE="0.4772727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3686739531172212" LOG_CI_START="-1.0111407166217574" LOG_EFFECT_SIZE="-0.3212333817522681" MODIFIED="2014-04-01 10:40:59 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.8105099671974472" STUDY_ID="STD-Hoge-2012" TOTAL_1="22" TOTAL_2="21" VAR="0.6569264069264069" WEIGHT="33.43470351497273"/>
<DICH_DATA CI_END="6.6053601716585275" CI_START="0.07037860479622056" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.8198965034492853" LOG_CI_START="-1.1525593469823354" LOG_EFFECT_SIZE="-0.16633142176652502" MODIFIED="2014-04-01 10:40:59 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.1586303303574623" STUDY_ID="STD-Pitman-2002" TOTAL_1="11" TOTAL_2="15" VAR="1.3424242424242425" WEIGHT="16.361548721048408"/>
<DICH_DATA CI_END="3.6560901830871733" CI_START="0.27351622906511786" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5630168997352268" LOG_CI_START="-0.563016899735227" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-01 10:40:59 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.6614378277661476" STUDY_ID="STD-Stein-2007" TOTAL_1="12" TOTAL_2="16" VAR="0.43749999999999994" WEIGHT="50.20374776397885"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-07-03 12:30:21 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Hydrocortisone versus placebo</NAME>
<DICH_OUTCOME CHI2="0.43447294466759073" CI_END="0.5577878211442382" CI_START="0.05123860974333498" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1690570095772274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.2535309724428547" LOG_CI_START="-1.2904026624751492" LOG_EFFECT_SIZE="-0.7719668174590019" METHOD="IV" MODIFIED="2014-07-01 13:56:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.933032661397813" P_Q="1.0" P_Z="0.0035178049126802446" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="80" WEIGHT="100.0" Z="2.918446272619374">
<NAME>Treatment efficacy</NAME>
<GROUP_LABEL_1>Hydrocortisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydrocortisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.824457464346881" CI_START="0.008156930437807791" EFFECT_SIZE="0.15178571428571427" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.45093503875068475" LOG_CI_START="-2.0884732413345" LOG_EFFECT_SIZE="-0.8187691012919077" MODIFIED="2013-11-28 19:00:39 +0000" MODIFIED_BY="Jonathan Ipser" ORDER="9" O_E="0.0" SE="1.4916609939957548" STUDY_ID="STD-Delahanty-2012" TOTAL_1="31" TOTAL_2="33" VAR="2.2250525210084033" WEIGHT="16.671895187405212"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-12-11 13:29:33 +0000" MODIFIED_BY="Jonathan Ipser" ORDER="12" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Schelling-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="35.57135574206396"/>
<DICH_DATA CI_END="2.6030369977158854" CI_START="0.03417179485701463" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4154803409058791" LOG_CI_START="-1.466332209494314" LOG_EFFECT_SIZE="-0.5254259342942175" MODIFIED="2013-12-11 13:29:33 +0000" MODIFIED_BY="Jonathan Ipser" ORDER="10" O_E="0.0" SE="1.1053860072274302" STUDY_ID="STD-Weis-2006" TOTAL_1="19" TOTAL_2="17" VAR="1.2218782249742002" WEIGHT="30.3596885994978"/>
<DICH_DATA CI_END="1.7184403754798798" CI_START="0.005613256098963373" EFFECT_SIZE="0.09821428571428571" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.23513446807097466" LOG_CI_START="-2.250785143094888" LOG_EFFECT_SIZE="-1.0078253375119566" MODIFIED="2013-12-11 12:42:07 +0000" MODIFIED_BY="Jonathan Ipser" ORDER="11" O_E="0.0" SE="1.4602414850993635" STUDY_ID="STD-Zohar-2011a" TOTAL_1="15" TOTAL_2="10" VAR="2.1323051948051948" WEIGHT="17.397060471033026"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3421574617595493" CI_END="0.6444345653852933" CI_START="0.06295760495889721" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20142506494819834" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.19082117347705158" LOG_CI_START="-1.200951801819885" LOG_EFFECT_SIZE="-0.6958864876484683" METHOD="MH" MODIFIED="2014-04-01 10:47:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9519142273532323" P_Q="1.0" P_Z="0.006924210722074504" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="57" WEIGHT="100.0" Z="2.7004674739080774">
<NAME>Sensitivity analysis - observed cases</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydrocortisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2592490689130895" CI_START="0.009783773632456663" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.5131175501311043" LOG_CI_START="-2.009493604143505" LOG_EFFECT_SIZE="-0.7481880270062004" MODIFIED="2014-04-01 09:00:17 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.481794279147509" STUDY_ID="STD-Delahanty-2012" TOTAL_1="19" TOTAL_2="24" VAR="2.1957142857142857" WEIGHT="16.034464327894806"/>
<DICH_DATA CI_END="1.1686648019733525" CI_START="0.026086409490581892" EFFECT_SIZE="0.1746031746031746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.06768996408888707" LOG_CI_START="-1.5835856926796006" LOG_EFFECT_SIZE="-0.7579478642953567" MODIFIED="2014-04-01 09:00:17 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.9699674947321383" STUDY_ID="STD-Schelling-2001" TOTAL_1="9" TOTAL_2="11" VAR="0.9408369408369407" WEIGHT="37.421045943641985"/>
<DICH_DATA CI_END="2.8288881074456356" CI_START="0.03927730857175531" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4516157699101712" LOG_CI_START="-1.405858279349496" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-04-01 09:00:17 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Weis-2006" TOTAL_1="14" TOTAL_2="14" VAR="1.1904761904761905" WEIGHT="29.573966006369176"/>
<DICH_DATA CI_END="2.1635709927301043" CI_START="0.0076404297804153745" EFFECT_SIZE="0.12857142857142856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.33517115016802096" LOG_CI_START="-2.1168822113178853" LOG_EFFECT_SIZE="-0.890855530574932" MODIFIED="2014-04-01 09:00:17 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.4403482823967175" STUDY_ID="STD-Zohar-2011a" TOTAL_1="9" TOTAL_2="8" VAR="2.0746031746031743" WEIGHT="16.970523722094022"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-07-02 14:47:34 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-07-02 14:47:34 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArMAAAQtCAYAAABJW8cSAACAAElEQVR42uy9Pe+8znU+vJJr146b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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-01 16:16:35 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm8AAAEACAMAAADSomGoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-01 16:16:35 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUgAAAKPCAIAAACAc8T1AABNoklEQVR42u29z4v0XJolpvrqP5mV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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-03-29 07:19:52 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="Chris Champion">
<APPENDIX ID="APP-01" MODIFIED="2014-07-01 16:14:54 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-07-01 13:59:04 +0100" MODIFIED_BY="[Empty name]">Search strategy (OVID MEDLINE, EMBASE)</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-01 16:14:54 +0100" MODIFIED_BY="[Empty name]">
<P>CCDAN's Trials Search Co-ordinator (TSC) ran the following searches on OVID MEDLINE and EMBASE:</P>
<P>
<B>(i) OVID MEDLINE (2004 to March 2011)</B>
</P>
<P>1. ((serotonin or norepinephrine or noradrenaline or dopamine or neurotransmitter) adj (uptake or reuptake or re-uptake)).mp.<BR/>2. (antiadrenergic or anti-adrenergic).mp.<BR/>3.  (5-hydroxytrypotophan or Acetylcarnitine or Alaproclate or alprazolam or Amersergide or Amiflamine or Amineptine or Amitriptyline or Amoxapine or anticonvulsant* or Antidepress* or antipsychotic* or anxiolytic* or Aripiprazole).mp.<BR/>4. (Befloxatone or Benactyzine or Benzodiazepine* or Brofaromine or Bupropion or Butriptyline).mp.<BR/>5. (Carbazepine or Caroxazone or cck-4 or Chlorimipramine or Chlorphenamidine or Chlorpoxiten or Cilosamine or Cimoxatone or Citalopram or Clomipramine or clonidine or Clorgyline or Clovoxamine or Cyproheptadine or d-Cycloserine).mp.<BR/>6. (Deanol or Demexiptiline or Deprenyl or Desipramine or Desvenlafaxine or Dibenzipin or Diclofensine or divalproex or dopamin* or Dosulepin or Dothiepin or Doxazosin or Doxepin or Duloxetine).mp.<BR/>7. (Escitalopram or Etoperidone or Femoxetine or Fenfluramine or flumazenil or Fluotracen or fluoxetine or Fluparoxan or fluphenazine or Fluvoxamine or Furazolidone or Guanfacine).mp.<BR/>8. (haloperidol or Harmaline or Harmine or hydrocortisone or Idazoxan or Imipramine or inositol or Iprindole or Iproniazid or Isocarboxazid or lamotrigine).mp.<BR/>9. (Lithium carbonate or Lithium compounds or Litoxetine or Lofepramine).mp.<BR/>10. (MAOI* or Maprotiline or medicat* or Medifoxamine or Melitracen or Metapramine or Metyrapone or Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Monoamine Oxidase Inhibitor*).mp.<BR/>11. (Naloxone or Naltrexone or Nefazodone or Nialamide or Nomifensine or noradrenerg* or Norfenfluramine or Nortriptyline or Noxiptiline or Olanzapine or Opipramol or Oxaflozane or Oxaprotiline or Oxcarbazepine).mp.<BR/>12. N-Methyl-3,4-methylenedioxyamphetamine/<BR/>13. (Pargyline or Paroxetine or pharmacother* or Phenelzine or Pheniprazine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Prazosin or Pregabalin or Procaine or Propranolol or Prosulpride or Protriptyline or psychotropic*).mp.<BR/>14. (Quetiapine or Quinupramine or Quipazine or Reboxetine or Risperidone or Ritanserin or Rolipram).mp.<BR/>15. (Selegiline or seroto* or Sertraline or Setiptiline or SNRI* or SSRI* or Sulpiride).mp.<BR/>16. (Teniloxine or Tetrindole or Thiazesim or Thozalinone or Tiagabine or Tianeptine or Toloxatone or Tomoxetine or Topiramate or Tranylcypromine or Trazodone or tricyclic* or Trimipramine or Tryptophan).mp.<BR/>17. (Venlafaxine or Viloxazine or Viqualine or Yohimbine or Zimeldine).mp.<BR/>18. exp Stress Disorders, Traumatic/dt<BR/>19. or/1-18<BR/>20. exp Stress Disorders, Traumatic/<BR/>21. ((post-traumatic or post traumatic or posttraumatic) and disorder*).tw.<BR/>22. PTSD.tw.<BR/>23. or/20-22<BR/>24. randomized controlled trial/<BR/>25. controlled clinical trial/<BR/>26. randomi#ed.ti,ab.<BR/>27. randomly.ab.<BR/>28. placebo$.tw.<BR/>29. trial.ab.<BR/>30. drug therapy.fs.<BR/>31. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp.<BR/>32. (control$ adj3 (trial$ or study or studies$ or group$)).tw.<BR/>33. (animals not (humans and animals)).sh.<BR/>34. or/24-32<BR/>35. 34 not 33<BR/>36. 19 and 23 and 35<BR/>37. (2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$).ed,yr.<BR/>38. 36 and 37</P>
<P>
<B>(ii) OVID EMBASE (2004 to February 2010)</B>
</P>
<P>1. ((seroton* or norepinephrine or noradrenaline or dopamin* or neurotransmitter) adj (uptake or reuptake or re-uptake)).mp.<BR/>2. (5-hydroxytrypotophan or acetylcarnitine or alaproclate or alprazolam or amersergide or amiflamine or amineptine or amitriptyline or amoxapine or anticonvulsant* or antidepress* or antipsychotic* or anxiolytic*).mp.<BR/>3. (befloxatone or benactyzine or benzodiazepine* or brofaromine or bupropion or butriptyline).mp.<BR/>4. (caroxazone or cck-4 or chlorimipramine or chlorphenamidine or chlorpoxiten or cilosamine or cimoxatone or citalopram or clomipramine or clonidine or clorgyline or clovoxamine or cyproheptadine or d-cycloserine).mp.<BR/>5. (deanol or demexiptiline or deprenyl or desipramine or desvenlafaxine or dibenzipin or diclofensine or divalproex or dopamin* or dosulepin or dothiepin or doxepin or duloxetine).mp.<BR/>6. (escitalopram or etoperidone or femoxetine or fenfluramine or flumazenil or fluotracen or fluoxetine or fluparoxan or fluphenazine or fluvoxamine or furazolidone).mp.<BR/>7. (haloperidol or harmaline or harmine or hydrocortisone or idazoxan or imipramine or inositol or iprindole or iproniazid or isocarboxazid or lamotrigine).mp.<BR/>8. (lithium carbonate or lithium compounds or litoxetine or lofepramine).mp.<BR/>9. (maoi* or maprotiline or medicat* or medifoxamine or melitracen or metapramine or metyrapone or mianserin or milnacipran or minaprine or mirtazapine or moclobemide or monoamine oxidase inhibitor*).mp.<BR/>10. (naloxone or naltrexone or nefazodone or nialamide or nomifensine or noradrenerg* or norfenfluramine or nortriptyline or noxiptiline or olanzapine or opipramol or oxaflozane or oxaprotiline).mp.<BR/>11. (pargyline or paroxetine or pharmacother* or phenelzine or pheniprazine or piribedil or pirlindole or pivagabine or pizotyline or prazosin or procaine or propranolol or prosulpride or protriptyline or psychotropic*).mp.<BR/>12. (quetiapine or quinupramine or quipazine or reboxetine or risperidone or ritanserin or rolipram).mp.<BR/>13. (selegiline or seroto* or sertraline or setiptiline or snri* or ssri* or sulpiride).mp.<BR/>14. (teniloxine or tetrindole or thiazesim or thozalinone or tiagabine or tianeptine or toloxatone or tomoxetine or topiramate or tranylcypromine or trazodone or tricyclic* or trimipramine or tryptophan).mp.<BR/>15. (venlafaxine or viloxazine or viqualine or yohimbine or zimeldine).mp.<BR/>16. or/1-15<BR/>17. posttraumatic stress disorder/<BR/>18. ((post-traumatic or post traumatic or posttraumatic) and disorder*).tw.<BR/>19. ptsd.tw.<BR/>20. or/17-19<BR/>21. major clinical study/<BR/>22. randomized controlled trial/<BR/>23. randomization/<BR/>24. placebo/<BR/>25. randomi#ed.ti,ab.<BR/>26. placebo$.tw.<BR/>27. trial$.ti,ab.<BR/>28. randomly.ab.<BR/>29. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp.<BR/>30. (control$ adj3 (trial$ or study or studies$)).tw.<BR/>31. ((animal or nonhuman) not (human and (animal or nonhuman))).de.<BR/>32. or/21-30<BR/>33. 32 not 31<BR/>34. 16 and 20 and 33<BR/>35. (2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$).yr,em.<BR/>36. 34 and 35</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-07-01 14:00:29 +0100" MODIFIED_BY="[Empty name]">Additional author searches (PubMed, PsycINFO, EMBASE)</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-01 14:01:33 +0100" MODIFIED_BY="[Empty name]">
<P>The authors ran additional searches (all years to March 2011) on the following databases, using the following terms:</P>
<P>
<B>(iii) PubMed</B>
<BR/>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ("latin square" [tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]) AND (Stress Disorders, Traumatic [mh] OR "acute stress disorder" [tw] OR ASD [tw] OR "posttraumatic stress disorder" [tw] OR "post traumatic stress disorder" [tw] OR PTSD [tw]) AND (prevent* [tw] OR prophy* [tw]).</P>
<P>
<B>(iv) PsycINFO</B>
<BR/>PsycINFO was searched using the following search query: ("randomisation" OR "randomization") OR "controlled" AND ("post traumatic stress disorder" OR "PTSD")</P>
<P>
<B>(v) EMBASE</B>
<BR/>EMBASE was searched using the following search strategy: (random* OR "controlled") AND ("post traumatic stress disorder" OR "PTSD") AND (prevent*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-07 15:40:12 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-07-01 13:59:40 +0100" MODIFIED_BY="[Empty name]">Systematic reviews search: PTSD/drug therapy (OVID MEDLINE)</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-08 08:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. (((systematic or structured or evidence or trials).ti. and ((review or overview or look or examination or update$ or summary).ti. or review.pt.)) or (meta analysis.pt. or meta analysis/ or "0266-4623".is.) or (reviewed systematically or systematically reviewed).tw. or (1469-493X or 1366-5278 or 1530-440X).is.) not ((animals/ not humans/) or letter.pt.)<BR/>2. ("review" or "review academic" or "review tutorial").pt.<BR/>3. (medline or medlars or embase or pubmed).tw,sh.<BR/>4. (scisearch or psychinfo or psycinfo).tw,sh.<BR/>5. (psychlit or psyclit).tw,sh.<BR/>6. cinahl.tw,sh.<BR/>7. ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh.<BR/>8. (electronic database$ or bibliographic database$ or computeri#ed database$ or online database$).tw,sh.<BR/>9. (pooling or pooled or mantel haenszel).tw,sh.<BR/>10. (retraction of publication or retracted publication).pt.<BR/>11. (peto or dersimonian or der simonian or fixed effect).tw,sh.<BR/>12. or/3-11<BR/>13. 2 and 12<BR/>14. meta-analysis.pt.<BR/>15. meta-analysis.sh.<BR/>16. (meta-analys$ or meta analys$ or metaanalys$).tw,sh.<BR/>17. (systematic$ adj5 review$).tw,sh.<BR/>18. (systematic$ adj5 overview$).tw,sh.<BR/>19. (quantitativ$ adj5 review$).tw,sh.<BR/>20. (quantitativ$ adj5 overview$).tw,sh.<BR/>21. (quantitativ$ adj5 synthesis$).tw,sh.<BR/>22. (methodologic$ adj5 review$).tw,sh.<BR/>23. (methodologic$ adj5 overview$).tw,sh.<BR/>24. (integrative research review$ or research integration).tw.<BR/>25. or/14-24<BR/>26. (1 or 13 or 25)<BR/>27. stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/<BR/>28. (PTSD or posttrauma* or post-trauma* or post trauma* or stress disorder* or combat disorder*).tw.<BR/>29. or/27-28<BR/>30. dt.fs.<BR/>31. (26 and 29 and 30)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-03-29 07:19:52 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;INCLUDED STUDIES: No. of studies included in the meta-analysis&lt;/p&gt;&lt;p&gt;Total = 9 studies&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;SCREENING 2: No. of full-text articles assessed&lt;/p&gt;&lt;p&gt;Total = 21&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="156">
<FLOWCHARTBOX TEXT="&lt;p&gt;SCREENING 1: No. of records after screening&lt;/p&gt;&lt;p&gt;a. CCDANCTR = &lt;span&gt;33&lt;/span&gt;&lt;/p&gt;&lt;p&gt;b. mRCT = 13&lt;/p&gt;&lt;p&gt;c. NIH (Reports) = 0&lt;/p&gt;&lt;p&gt;d. WHO Trials = 6&lt;/p&gt;&lt;p&gt;UPDATED SEARCHES&lt;/p&gt;&lt;p&gt;e. CCDANCTR = 13&lt;/p&gt;&lt;p&gt;&lt;span&gt;f. OVID MEDLINE = 1&lt;/span&gt;&lt;/p&gt;&lt;p&gt;g. mRCT = 3&lt;/p&gt;&lt;p&gt;h. NIH (RePort) = 0&lt;/p&gt;&lt;p&gt;i. WHO Trials = 2&lt;/p&gt;&lt;p&gt;Records = 71&lt;/p&gt;" WIDTH="181">
<FLOWCHARTBOX TEXT="&lt;p&gt;SEARCH PROCESS 1 (CCDAN):&lt;/p&gt;&lt;p&gt;(a) CCDANCTR&lt;/p&gt;&lt;p&gt;CCDANCTR (2010, 2011) = &lt;span&gt;714 &lt;/span&gt;&lt;/p&gt;&lt;p&gt;CCDANCTR (2012) = 1291&lt;/p&gt;&lt;p&gt;CCDANCTR (2014) = 7&lt;/p&gt;&lt;p&gt;(b) OVID MEDLINE = 87&lt;/p&gt;&lt;p&gt;Records = 2099&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="215">
<OUT TEXT="&lt;p&gt;SEARCH PROCESS 2: Additional resources (2012)&lt;/p&gt;&lt;p&gt;a. mRCT = 134&lt;/p&gt;&lt;p&gt;b. NIH (RePort) = 694&lt;/p&gt;&lt;p&gt;UPDATED SEARCH (2013)&lt;/p&gt;&lt;p&gt;c. mRCT = 151&lt;/p&gt;&lt;p&gt;d. NIH (RePort) = 247&lt;/p&gt;&lt;p&gt;Records = 1226&lt;/p&gt;" WIDTH="175"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;SEARCH PROCESS 3: Clinical Trials (2012)&lt;/p&gt;&lt;p&gt;a. WHO Trials = 568&lt;/p&gt;&lt;p&gt;UPDATED SEARCH (2013)&lt;/p&gt;&lt;p&gt;b. WHO Trials = 99&lt;/p&gt;&lt;p&gt;Records = 667&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="175"/>
<OUT TEXT="&lt;p&gt;No. of records excluded after screening&lt;/p&gt;&lt;p&gt;Total = 50&lt;/p&gt;&lt;p&gt;Reasons for exclusion:&lt;/p&gt;&lt;p&gt;Did not meet inclusion criteria&lt;/p&gt;" WIDTH="172"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;No. of full-text articles excluded&lt;/p&gt;&lt;p&gt;Total = 12 studies&lt;/p&gt;&lt;p&gt;Reasons for exclusion:&lt;/p&gt;&lt;p&gt;Relapse prevention studies = 3&lt;/p&gt;&lt;p&gt;Non randomised trials = 3&lt;/p&gt;&lt;p&gt;Ongoing studies = 3&lt;/p&gt;&lt;p&gt;Studies awaiting classification = 3&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="169"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>